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Cancer Initiating Cells (CIC) have been shown to be present in various cancer types 
and characterised as highly tumorigenic, drug resistant and invasive sub-population. 
Identifying CIC in patient samples has been primarily done using flow cytometry with 
a few markers such as CD44, CD24 in breast cancer and CD38, CD34 in leukemia. 
Newer markers and signalling pathways are being identified as potential CIC markers 
and therapeutic targets but identifying CIC in tumors has been elusive.  
We wanted to look at the CIC question in perspective of its environment and 
understand how cancer initiating cells interact with its environment in the micro and 
macro scale. We wanted to identify possible patterns of CIC interactions with ECM 
proteins such as collagen and fibronectin that can help us identify them in tumor 
samples. To enable us to answer these questions we established the CIC/non CIC 
model using a breast cancer cell line MX-1. We established in-vitro methodologies to 
study fibonectin fibres and collagen gel remodelling by CIC in bulk cultures and 
microfluidic channels. We established animal models to study the macro and micro 
interactions of CIC with its environment. We developed and improved Second 
Harmonic Generation (SHG) imaging tool to study collagen remodelling in tumor 
specimens without the need for staining and tedious sample preparation. 
We have demonstrated that cancer initiating cells (CIC) are fundamentally different 
from the majority cancer population which we refer to as the non-CIC. We have 
isolated CIC from immortalized cancer cell lines such as MCF-7, MX-1, MDA-MB 
231, HepG2 and Huh-7. We also demonstrate that the CIC isolated from MX-1 have 







We studied the CIC interacting with its environment in-vivo using a short term skin 
flap assay and a long term xenograft assay. In the skin flap technique we injected CIC 
in the blood vessel of an animal and observed the CIC forming colonies under the 
skin and extravasating into the surrounding tissue regions. The extent of colonisation 
and extravasation in CIC was significantly more than non-CIC. In the long term 
xenograft assay CIC and non CIC were injected subcutaneously in animals and CIC 
consistently formed tumors in all the animals injected with 100,000 of these cells 
while the non-CIC is able to form tumor only in one in five animals even though 10 
million cells were injected. 
We improved the SHG imaging microscope using a pulse compressor set up to 
reverse the problem of group velocity dispersion and hence enhance the signal to 
noise ratio. We achieved a 6x higher SBR using our pulse compressor. The tumors 
formed by CIC and non-CIC were harvested and studied using our improved SHG 
imaging system to visualise the collagen patterns in the tumors. The CIC tumors 
consistently had less collagen area percentage and distinct collagen remodelling 
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Cancer is one of the greatest medical challenges in Singapore with the number 
of cancer patients increasing every year [1]. Breast cancer is one of the leading killers 
of women in Singapore. Breast cancer is relatively easier to detect and treat compared 
to other cancers of the internal organs[2]. Nonetheless the treatment success remains 
low and the recurrence rate of the disease is quite high. Recent works have attributed 
this lower success and higher recurrence to a rare population of cells present in the 
bulk of the tumor called cancer initiating cells (CIC). The CIC population has drug 
resistance enabling them to escape treatment and feeds tumor growth lowering 
treatment success. And when the treatment regimen is good enough to kill the bulk of 
the tumor these rare cells remain dormant in the host body and leads to disease 
recurrence later on [3-5].  
There are two hypotheses on how these cells could arise. Firstly the 
hierarchical model suggests that cancer is a monoclonal disease that has its origin 
from a deregulated stem cell [6]. A stem cell that accumulates enough mutations 
could become a cancer stem cell and thus generate a hierarchy of cancer cells from 
the primary to more differentiated cells [7-8]. As the cancer stem cell arises from a 
stem cell they have inherent chemo-protective mechanisms such as molecular pumps 
enabling them to survive harsh environments. The second hypothesis is the stochastic 
model where a cell in the body accumulates mutations over time and these random 
mutations trigger molecular processes that makes it a stem like cell. This hypothesis 
supports the fact that the cancer stem cells isolated from patient samples do not have 
all stem cell properties but only a few that enables them to survive and multiply 
indefinitely [9].  
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Whatever is the source of these cancer stem cells or cancer initiating cells it 
has been shown in literature that these cells can be isolated from patient samples and 
cancer cell lines. The cancer cells can be separated into a minority cancer stem cell or 
initiating cell population and a majority non stem or non-initiating population based 
on several properties such as their marker profiles [10-14], their drug effluxing 
properties [15-16] their ability to grow as spheroids independent of the culture 
substrate [17] or their protease activity levels [18-19]. 
The CIC that were isolated were shown to have several stem cell properties 
such as over-expression of c-kit, oct-4 and Sca-1 in certain cancer types [17, 20], 
capacity to differentiate into different lineages of that particular tissue type and 
chemo-protective properties [16, 21]. These CIC have the capacity to generate a 
tumor only when about a 100 of these cells were injected into the animal, while more 
than 10 million non-CIC were required to generate a tumor and in certain other cases 
non-CIC could not generate a tumor at all [15, 22]. The properties of the CIC point to 
the fact that if identified and characterized in vivo, we will be able to better diagnose 
the disease as well design new treatment methods to target these cells.  
All the aforementioned literature has been focusing on the properties of CIC 
either in in-vitro or in-vivo systems as a stand-alone group of cells. But we know that 
all cancer cells take cues from their neighbors and the microenvironment to survive, 
divide, invade and sometimes to die [23-25]. Extra cellular matrix molecules such as 
collagen, fibronectin and other soluble molecules in the microenvironment niche and 
host derived cells such as endothelial cells and vascular progenitor cells have been 
shown to control how the cancer cells forms tumors, expand the tumor mass, develop 
blood vessels and metastasize [26-27]. The cancer cells have complex methods of 
ECM creation and degradation that enables in maintaining the structure of the tumor 
 3 
as well as provide for the nutrition and oxygen supply through the blood vessel 
system [28].  
We have approached this problem of cancer initiating cells with the 
microenvironment in perspective. We chose collagen as the extra cellular molecule 
that we could visualize in the CIC and non-CIC tumors to see how different the ECM 
remodeling is in the two systems. There are three main reasons to choose collagen as 
our molecule of interest. 1. Collagen is ubiquitously present in all tissue types and 
they are one of the main ECM molecules that provide both structural support and 
molecular signalling. 2. We have developed Second Harmonic Generation Imaging 
microscope (SHIM) in the lab that can visualize collagen without any staining and 
sectioning thus providing an easy to use clinical tool. 3. If we do find differentiating 
ECM remodeling patterns between the CIC and non-CIC groups we can further this 
study to clinical samples to find unique signatures that might predict the severity, 
stage and presence or absence of CIC. 
SHIM works on the principle of Second Harmonic Generation (SHG) where 
the light interacts with materials with second order susceptibility and generate 
transmitted or reflected beam with half the wavelength or twice the frequency of the 
original light [29]. Most materials have very low second order susceptibility and 
hence the SHG signals generated by these materials cannot be detected. But non-
centrosymmetric materials such as collagen on the other hand have high second order 
susceptibility, thus making collagen a suitable biomolecule for SHG imaging [30]. 
All microscopes have the problem of group velocity dispersion (GVD).  When 
the beam passes through optical components like lenses and beam splitters the lower 
wavelength component of light will travel slower than the higher wavelength 
component leading to a temporal stretch in the beam. This is called negative GVD. 
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The GVD is an issue of concern in SHG microscopes as the laser beam used to excite 
the samples are femto-second pulses and a 50fs laser pulse after GVD could be 
stretched to a 200 fs pulse. This reduces peak power delivered to the sample, reducing 
the efficiency of SHG.  
GVD can be reversed using pulse modulation. With the use of chirped mirrors, 
grating or prism pairs, the velocity of the higher and lower wavelength components of 
the beams can be altered to restore the beam to the native temporal width. In our work 
we have used the prism pair pulse compressor set up to reverse negative GVD. We 
would like to demonstrate that pulse compression improves the efficiency of second 
harmonic generation and thus enable us to detect even the smaller collagen fibrils that 
remain undetected with GVD.  
Along with the CIC – ECM remodeling hypotheses, another venue we were 
interested to use the SHG system was to visualize collagen remodeling in drug treated 
tumors. It has been shown that the collagen fibers in the tumor limit the drug diffusion 
into the tumor and the use of relaxin and collagen degrading enzymes can improve 
drug penetration in the tumor and hence result in higher drug efficacy [31]. On the 
other hand it also has been shown that collagen fibers are in reduced numbers in 
tumor tissues compared to normal tissues [32]. We wanted to assess if the cancer cells 
modulated their collagen production in the presence of chemotherapeutic agents. We 
will also assess the maturity of the collagen fibers in the tumor samples after drug 
treatment to quantify the collagen remodeling in drug treated tumors. 
In summary, the final objective of this project is to test the hypothesis that the 
CIC have different ECM remodeling properties in vivo compared to non-CIC. We 
would like to prove that CIC is unique in a quantitative manner in vitro and in vivo. In 
order to achieve that, we devise appropriate method to isolate CIC (aim 1), develop 
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and validate imaging method to visualize ECM in vivo (aim 2, 3) and use the tool to 
visualize CIC-ECM interactions (aim 4). The ECM remodeling capacity of this sub 
population can be used as a signature to identify this population in animal models for 
drug development studies. In the future CIC can be detected in patient samples to 
tailor therapies to target and eliminate CIC. To aid us in this validation we use the 
improved SHG microscope. We also explore the collagen remodeling properties of 
drug treated tumor samples to understand ECM in the context of chemotherapy 
regimens as well as to validate the improvement conferred to the SHG system with 
pulse compression.  
The uniqueness of our approach lies in the focus on spatial and temporal 
analysis of cancer cell-matrix interaction in animal models. Our primary focus is the 
comparative study of the growth rate and vascularization and their relationship to 
ECM remodeling utilizing advanced imaging methods. The four specific aims are 
designed to achieve the aforementioned objectives.  
 
Specific Aim 1: To isolate and characterize a highly tumorigenic sub-population in 
cancer cell lines using side Population analysis 
Hypothesis 1: The cancer cell line population can be sorted into highly tumorigenic 
and less tumorigenic sub populations based on certain markers and/or their dye 
effluxing capabilities due to the multiple drug resistance (MDR) proteins. 
 
Supporting Evidence: 
Firstly, Cancer initiating cells (CIC) cells have been isolated using various methods in 
different types of cancer. Side population (SP) method is one such technique used to 
isolate CIC. Its application has been demonstrated in the cancers of the blood, brain, 
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breast, liver and ovaries [16]. The side population is named so due to the distinct tail 
like pattern that is formed during the flow cytometric analysis of these cells. Secondly 
these isolated sub population can asymmetrically divide to generate both the side and 
non-side population enabling faster growth of tumors. The SP express higher levels of 
VEGF; hence the tumors have better vasculature [33]. Thirdly this sub population is 
drug resistant (expressing higher levels of Multi drug resistance (MDR) or ATP 
Binding Cassette (ABC) proteins) [16].  
 
Experimental Approach: 
 Side population isolation using fluorescence Activated Cell Sorting (FACS)  
 Characterizing the CD44 and CD24 expression patterns of the side population 
 Cell proliferation comparison of the CIC and non CIC 
 Drug resistance studies before sorting 
 Drug resistance studies after sorting 
  
Specific Aim 2: Developing tools and methods to visualize collagen and to correlate 
collagen remodeling by cancer cells to growth and vascularisation in conventional 
animal models.  
Hypothesis 2: Extra cellular matrix (ECM) remodeling by cancer cells can be 
correlated to its tumor growth and vascularisation. 
 
Supporting Evidence:  
During the various phases of cancer, proteolytic ECM remodeling by the cancer cells 
and cell - ECM interaction play a decisive role [34]. Cancer cells needs to interact and 
remodel surrounding ECM for it to escape and metastasize [35]. Matrix 
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metalloproteinase (MMPs) are crucial proteases, which break down ECM for tumor 
progression and angiogenesis. Over expression of MMP1 due to Single nucleotide 
polymorphism (SNP) has been often found in cancer cell line and certain ovarian 
cancer patients [36].  
 
Experimental Approach: 
 Development of the Second Harmonic Generation (SHG) system for ECM 
visualization  
 Improvement of the SHG system with pulse compressor 
 Tumor growth and metastasis visualization using OV100  
 Developing image processing algorithms to quantify and correlate spatial and 
temporal growth patterns and vascularization to ECM distribution 
 
Specific Aim 3: To visualize collagen remodeling in drug treated tumor samples 
utilizing the improved SHG system and use this data to validate the improvement. 
 
Hypothesis 3:  Collagen remodeling is altered in tumors upon drug administration 




 Collagen fibers in tumors have shown to hinder drug diffusion in animal 
models and cancer cells grown in 3D show higher mRNA expression of collagen 
upon drug treatment. It also has been shown that the tumor interior has lesser collagen 
than normal tissues using SHG. Thus we believe that the improved SHG will be able 
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to visualize even the small collagen fibers in the tumor interior and a difference 
between drug treated and control samples can be quantitatively determined.    
 
Experimental approach: 
 Develop drug treated and control xenograft models 
 Visualize collagen using SHG microscope to obtain forward and backward 
SHG signal with and without pulse compression . 
 Using the developed image processing algorithms to quantify collagen fiber 
length, width, number and area percentage in the drug treated group and 
control group tumor with and without pulse compression to validate 
improvement using pulse compression 
 
Specific Aim 4: To utilize the above developed imaging tool to compare the spatial 
and temporal dynamics of the side population and non - side population of cancer 
cells in animal models. 
Hypothesis 4: The side population has different ECM remodeling capabilities 
compared to the non- side population. 
 
Supporting evidence:  
This sub population has been proven to have superior tumor formation 
properties in animal models [15, 17] and have better vascularization [4]. The 
metastatic potential, ECM remodeling capabilities and the inter relationship between 




 Develop animal models for CIC and non-CIC cells 
 Imaging to visualize growth rate, metastasis, angiogenesis and ECM 
remodeling using OV100 and the SHG microscope. 
 Using the developed image processing algorithms to correlate and compare 
tumor growth, ECM remodeling and vasculature for the two sub populations. 
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Figure 1: Schematic representation of the overall flow of the project. 
The development of animal models, the appropriate tools such as SHG microscope with pulse 
compressor improvement and the software quantification algorithm development to assess the 
ECM remodelling property of CIC in vivo are shown here. 
II Background and Significance 
This chapter provides the background information that defines the rationale for this 
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thesis work. The chapter is divided into (1) background information on cancer 
initiating cells with a focus on breast cancer - this section provides information on 
breast cancer with the strategies of isolating and characterizing initiating cells and 
clinical translation of the CIC concept, (2) cancer and its microenvironment and the 
available tools to study cancer-microenvironment interactions – this section discusses 
the interdependence of cancer and its microenvironment with the limitations of tools 
in characterizing the microenvironment, and (3) an introduction to Second Harmonic 
Generation (SHG) imaging and how this tool is useful to study cancer - ECM 
interactions - current limitation and improvement of the SHG microscope are 
discussed. 
 
2.1 Breast Cancer Initiating Cells 
2.1.1 Origins of Breast Cancer  
 
Figure 2: Structure of the female breast and carcinoma development in the breast 
(www.breastcancer.org) 
Breast is a highly vascularised organ with extensive blood and lymph vessel network. 2a shows 
the lymphatic network of a female breast. Cancers in the breast develop with accumulated 
mutations in the ductal or lobular epithelia giving rise to ductal (2b) or lobular (2c) carcinoma, 
where the cancer progresses in several stages from hyperplasia to invasive carcinoma. Labels in 
2c – A ducts B lobules C dilated section of duct to hold milk D nipple E fat F pectoralis major 
muscle G chest wall/rib cage Enlargement: A normal lobular cells B lobular cancer cells C 




 The most common causes of breast cancer are hereditary or acquired genetic 
mutations (BRCA1, BRCA2) [Brody], late or no pregnancies [Kelsey 1993], no breast 
feeding, hormone replacement therapies [Kelsey 1988] exposure to radiation [37]. 
There could be several known risk factors but cancer starts with a cell acquiring 
mutations and resist cell death or apoptosis. The acquired mutations will result in a 
group of cancer cells that can divide rapidly, resist drug administrations, invade local 
organs and metastasize to other organs of the body [38]. In breast cancer the cells 
acquiring such mutations can be of different epithelial lineages such as the lobular 
epithelium or the ductal epithelium [39]. When these normal cells acquire mutation 
there is increase in cell mass which is called hyperplasia [40]. If the cell proliferation 
is extensive but the cells have not invaded the basement membrane it is called 
carcinoma in-situ [41]. But when the cancer cells escape the single duct or gland and 
starts spreading to the other ducts and glands it is called invasive carcinoma [42]. 
Breast is a well vascularised organ with extensive blood and lymphatic vessel 
network. So when the invasive carcinoma cells reach the blood or lymph vessels they 
might metastasize to other organs such as the lungs and the bones where they form 
secondary tumors. This topic of invasion, migration and metastasis has been under 




2.1.2 Breast Cancer as a stem cell disease 
In normal stem cell hierarchy, there is a group of stem cells that divide 
asymmetrically to generate transit amplifying clusters of progenitor cells. The 
progenitor cells divide and differentiate further to become specialised cells with 
unique characteristics and functions. As we go down the hierarchy from stem cells to 
the differentiated cells, the replication potential of the cells is reduced [Fig 3A]. 
 
Figure 3: Differentiation of normal stem cells maintaining asymmetric division vs. Cancer stem 
cells [6] 
Stem cells in their niche divide asymmetrically to generate transit amplifying progenitor cells as 
well as stem cells, thus ensuring its own maintenance. The progenitor cells go on to divide and 
differentiate until they become terminally differentiated cells, which have little or no replication 
potential(A). on the other hand CIC loose the context of niche control and divide uncontrollably 
to form tumors, generating progenitor or differentiated cells with little control of replication 
potential (B). 
Many predict that the cancer causing mutations occur to less differentiated progenitor 
cells in the stem cell hierarchy, rather than the terminally differentiated cells, giving 
rise to cancer stem cell or cancer initiating cells (CIC). Or if the mutation happens to 
be a random phenomenon, the cells that acquire a unique set of mutations become 
partially stem cell like regaining their potential to replicate and maintain the small 
stem cell like population even without a unique niche. These are the cells that can 
survive and divide many folds to generate the tumor mass [Fig 3B]. The presence of 
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CIC – whether generated from stem cells or from differentiated cells – has been 
demonstrated in several cancers, several cell lines and various clinical samples. 
2.1.3 Isolation and Characterization of Cancer Stem Cells or Cancer Initiating 
Cells 
It has been hypothesized and demonstrated that the minority CIC population 
contributes to tumorigenesis and tumor growth where CIC cells can form tumors 
when only 100 CIC are implanted in an animal while atleast a million non-CIC cells 
are needed to form a tumor [17]. It has also been shown the CIC gives rise to the 
majority non-CIC population demonstrating asymmetric division [16]. In other words 
CIC is the fountain head of tumorigenesis, tumor growth and development. This 
minority CIC population is highly tumorigenic, invasive, metastatic, and it can 
effectively efflux the drugs administered to treat the cancer[45]. Various research 
groups have identified CIC using various techniques and they have named them 
differently. A few accepted terminologies are cancer stem cell, cancer initiating cells 
and also the side population due to its profile on flow analysis when stained with the 
Hoechst dye. When stained at 5 µg/ml, these cells can efflux the dye effectively 
because of which they appear as a “side population” distinctly separated from the 
majority of the cells. These cells are found to express certain stem cell markers like 
the C-Kit, Oct4 etc [17]. There have been striking similarities between this 
subpopulation and normal stem cells in properties like self renewal, migration, drug 
resistance, and immortality/longevity [46]. Hence the deduction that cancer originates 
from a deregulated stem cell. The following tables highlight the initiating cell 







Table 1: Various breast cancer cell lines have been characterized based on their expression of CD44 and CD24 to 
analyze for the presence of cancer initiating cells and progenitor properties of these CIC [47] 
 
 Cancer Initiating Cells isolated using molecular markers  
Source Type CIC marker   References 























  [11] 
Brain 
Medulloblastomas, 
glioblastomas, primary brain 
tumor CD133
+
   [50-52] 
Lung Non–small cell lung cancers Sca-1+ CD34+ Lin-  [53-54] 
Skin Metastatic melanoma CD20
+
   [55] 






  [56] 
Colon Colon adenocarcinoma CD133
+
   [57] 








Head and neck squamous cell 
carcinoma CD44
+
   [59] 
 
 
Table 3         
Cancer Initiating Cells isolated using SP method       
Source Type Sample   References 
Blood AML Blast cells Primary  [60] 
Brain Neuroblastoma Primary  [16] 
 Neuroblastoma B104  [61] 
 Glioblastoma, astrocytoma U87MG  [16] 
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 Brain glioma HS683  [16] 
 Glioma 
D54, U87, 
U251, U373 [62] 
Breast Adenocarcinoma  
SK-BR-3, MCF-
7 [16, 61] 
Cervix, Ovary and 
Prostate Ovarian ascite cells Primary  [63] 
 Ovarian Cancer cell lines 
IGROV-1, 
OVCAR-8 [63] 
 Ovarian adenocarcinoma SKOV3  [16] 








SW480, HSC15  
Pancreatic Cancer PK9, PK45H   [64] 
Table 2: List of various types of cancers in which cancer initiating cells are isolated using marker 
profiles 
Table 3: List of various cancer cell lines and primary samples in which cancer initiating cells are 
isolated using side population method 
 
2.1.3.1. Previous studies on Breast cancer initiating cells 
 CIC have been isolated based on various strategies. R.B. Clarke and his group 
have demonstrated that the sub population can be isolated using the side population 
analysis. This population is enriched in cells expressing putative stem cell markers 
p21, CK19 and musashi-1 along with ER alpha and Progesterone receptor. They are 
also proven to be undifferentiated since they lack myoepithelial and luminal specific 
cell antigen. Moreover these cells have superior colony formation capacity compared 
to the non-side population [65]. Other groups have cultured single cell suspension in 
medium supporting undifferentiated cells. They obtained clusters of cells, which are 
capable of growth in suspension. Moreover when these cells are dissociated, they 
were able to form clusters again. This elicits the fact that these cells have self-renewal 
properties. These clusters of cells were called mammospheres since they resemble 
neurospheres (neural stem cells) that are cultured in suspension [66]. In breast cancer 
this sub population is found to over express CD44 and have low or no expression of 
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 strategy [22, 66]. 
Animal models of this SP and non-SP have demonstrated that SP induces tumor 
formation in as low numbers as 10
3
 while the non-SP requires at least 10
6
 cells or 
more to induce cancer [17]. 
 
2.1.3.2. Studies on CIC in other cancers 
Cancer initiating cells were initially isolated from blood related cancers and 
hence one of the most well studied model systems in the cancer stem cell domain [67-
68], In case of blood cancer there are various stages in which the Hematopoetic stem 
cell can be deregulated to generate cancer stem cells [69]. In case of acute myeloid 
leukemia, animal studies have shown that the deregulated stem cell possesses the 
differentiative and proliferative capacities and the potential for self-renewal expected 
as a leukemic stem cell, suggesting that normal primitive cells rather than committed 
progenitor cells are the target for leukemic transformation [70].Some of the other 
cancers in which CIC’s have been isolated and characterized are in the cancers of  the 
breast, brain, liver and lung. In case of neuroblastoma, the SP has been proven to have 
higher expression of ATP binding cassette proteins like ABCG2 and ABCC3. These 
ABC proteins are molecular pumps that endow the cancer cells the potential to efflux 
the drugs administered to them. The CIC survive better and can form colonies in the 
presence of the drug mitoxantrone [16]. Recently CIC have been isolated in ovarian 
cancer patient samples [63], colorectal cancer [71], and melanomas [55] as well. The 
above studies on these different cancer initiating cell populations provide hints on the 
unique properties of this population which might be the fountainhead of tumor 
development as the cells responsible for the initiation, maintenance and growth of 









Figure 4: Strategies to target and eradicate CIC and the whole tumor [74]   
On ascertaining the presence of CIC in a tumor mass, the tumors can be eliminated in a multi-
pronged approach. The CIC can be killed targeting the signaling molecules that are involved 
with CIC. The reactive oxygen species (ROS) status of the CIC can be exploited to target them. 
The nutrition and oxygen supply to the tumors can be cut off using anti-angiogenic compounds 
choking the tumors The CIC can be forced to differentiate using factors such as bone 
morphogenetic proteins (BMPs) and lose its stem like phenotype giving a better chance for 




Prior works have mainly focused on various strategies of isolating the side population 
and in in-vitro characterization techniques of CIC (Table 3). The published animal 
studies assess only the tumorigenicity of CIC and the minimum number of CIC 
required to grow tumors. Further characterization of the tumor formed by CIC is 
lacking. There are several proposed ways of targeting cancer stem cells in the tumor. 
The CIC have been shown to be associated with several signaling pathways such as 
the NF-Kappa-B [Liu].  Wnt [Lindvall]  , Notch [Farnie] signalling pathways in vitro. 
But the inter-relationships of these proteins and CIC in-vivo have not been 
established. Identifying CIC in-vivo is a challenge due to their small numbers. But if 
we do develop a technique to identify the presence of CIC in-vivo we can utilize a 
multi-pronged approach to either target these cells directly or by driving them towards 
differentiation and then killing them using traditional methods (Fig 4) [Carol Tang]. 
As identifying this small population in a tumor by traditional immunochemistry 
techniques is very difficult, and also with limited availability of tumor tissue from 
patient biopsies, we devised an alternate strategy. 
There has been a growing body of evidence that cancer cells need a suitable 
microenvironment to establish and maintain a tumor and cancer cells suitably remodel 
their environment and establish a niche for sustenance. Thus we set out to study the 
interaction of the CIC with the stroma. We used animal models to gain valuable 
information on ECM remodeling by cancer initiating cells and identify if there are any 
hallmarks of ECM remodeling by CIC in tumors that can be translated to clinical 
studies. If we can demonstrate that CIC remodel the matrix significantly differently 
compared to the non-CIC, we can identify such features from clinical patient samples 
proving the presence of CIC. Therapies can then be designed to appropriately 
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eradicate the tumor. 
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2.2 Breast Cancer and its microenvironment 
2.2.1 Changes in microenvironment with Cancer Progression 
 
Figure 5: A schematic to show the host –tumor relationship 
The cancer cells remodel the matrix environment to establish a tumour niche. (a) The cancer 
cells signal the non-cancerous neighbouring cells such as fibroblasts and endothelial cell. (b) The 
cancer cells and the stimulated neighbours secrete matrix metalloproteinase and other enzymes 
to degrade the matrix and facilitate tumor growth. (c) The cells secrete factors such as Vascular 
Endothelial Growth Factor (VEGF) to attract endothelial cells and precursors for angiogenesis 
and vascularisation of the tumor to supply the cells with nutrients and oxygen. The cancer cells 
also secrete new matrix components at other regions to provide mechanical support required for 
the cancer cells 
 
The three defining characteristics of tumors are its proliferation rate and tumor 
size, lymph node involvement and metastatic potential, using which medical 
practitioners grade the tumor [75]. There are some theories that vascularization and 
metastasis are closely related, stating that formation of vessels can aid in the escape of 
cancer cells to invade distant organs [76]. An overlying factor that affects all stages of 
tumorigenesis, vascularization and tumor metastasis is the microenvironment. It is a 
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proven fact that cancer cells need a suitable environment to form a tumor [77]. The 
extracellular matrix (ECM) was believed to be just a scaffold providing physical 
support [78]. But it has been unraveled that there are mechanical and chemical cues 
that transact between cells and the ECM they reside in. In several organ systems it has 
been shown that cues from ECM are required for systematic development of the 
organ. But in case of cancers, the ECM – tumor relationship is altered compared to 
that of a normal organ. Whether the cues are aberrant or whether the aberrant cancer 
cells interpret the cues differently is not clearly understood. Whether the unique 
nature of a cancer microenvironment is a cause or an effect of tumorigenesis is yet to 
be explored. 
The cancer cells establish this niche by recruiting host derived cells and 
altering the matrix components such as collagen, fibronectin, laminin etc. while these 
ECM molecules provide signalling to the cancer cells through cell transmembrane 
glycoproteins – integrins. The signalling from the ECM affects an array of cellular 
processes anything from cell shape, attachment, motility, transcription, synthesis and 
secretion. Remodeling the matrix surrounding the cancer cells principally creates a 
niche for the tumor to grow as well as help to generate new vessels [79]. 
Matrixmetalloproteinases and other proteases are the key players in this remodeling 
process.  MMPs are both released by the cancer cell (e.g. MMP7) as well as the host 
derived cells like the endothelial cells, inflammatory cells, and myofibroblasts. The 
fibroblasts in the cancer niche are activated and they have a wound healing phenotype 
[80]. These peritumoral fibroblasts or Tumor activated fibroblasts help tumor 
progression by secreting MMPs [81-82]. Cancer cells and the surrounding ECM 
provide angiogenic cues to the host derived cells. The cancer cells directly attract 
host-derived cells by releasing chemokines and cytokines. The cancer cells also 
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remodel the surrounding ECM and secrete ECM components that attract host derived 
cells. These cues reach the host derived cells through various signaling pathways 
including tyrosine kinase, Smad, Ras, PI3K [83-84] 
The cues provided by the microenvironment plays a crucial role for the tumors 
to establish vasculature as well as to establish metastatic sites [85-87]. Studies have 
shown that cancer cells specifically recruit mesenchymal stem cells from the bone 
marrow. These cells signal the cancer cells in a paracrine fashion making them more 
metastatic [88].  The cells that acquire the metastatic phenotype escape to form 
transit-amplifying clusters. These clusters can further go on to metastasize at specific 
sites. The importance of microenvironment is clearly elucidated by the fact that 
cancers can metastasize to specific organs attracted by ligands produced by the 
metastatic site ECM (e.g. osteonectin released by bone marrow ECM attracts breast 
cancer cells to specifically metastasize to the bone) [68]. The bone is rich in cytokines 
and chemokines released for the interaction amongst the osteoblasts and osteoclasts. 
The developing bone is also rich in vasculature allowing easy passage of metastatic 
cells [89].  
Hence it is evident that the tumor cells, host derived cells and the tumor 
microenvironment work together in complex coordination to ensure the survival, 
proliferation and spreading of tumor. A quantitative observation and characterization 
of this ECM remodeling especially in the case of side population will give us useful 






2.2.2 Current Techniques and its limitations in extra cellular matrix 
(ECM) Characterization 
2.2.2.1 In vitro Studies of the components of cancer microenvironment 
The interplay of cancer cells, host derived cells and the ECM has been studied 
using several in vitro approaches in the gene and protein levels [90-91]. Recently 
proteomic and genome wide studies have resulted in uncovering several interactions 
between chemokines, cytokines and their receptors on cell surfaces. Proteomic and 
Genomic array studies, imaging and histochemical methods are some of the 
techniques employed to uncover the interplay between these molecules [92-94]. Other 
than these assays to understand the chemical relationships between the cancer and its 
microenvironment, there are mechanical factors that come into play which has also 
been attributed to the establishment of the tumor niche [95]. 
The following table illustrates a few model molecules implicated in cancer, ECM and 
host cell interaction. These are representative studies that provide us insights into the 
complicated tumor – host interaction. We will be able to study the molecular 













Table 4: A list of extracellular matrix factors with distinct roles in tumor initiation, progression 
and invasion 
Biomolecule Role in Cancer Development 
1. Heparanase [96] Over expressed in certain cancers 
Involved in ECM degradation and remodeling 
Involved in endothelial cell migration 
2. Prolidase [97] Catalyze the final stages of Collagen degradation 
Observed in breast cancer patients 
3. Matrixmetalloproteinases 
(MMP) 
Tissue inhibitor of MMP (TIMP) 
 [85, 98]  
ECM remodeling surrounding the tumor 
Released by cancer cells and host derived cells 
Observed in various cancers 
4. TGF- β [99] Promote cancer metastasis by 
Effect on the tumor microenvironment 
Enhances cancer cell invasive properties 
Inhibit  immune cell function 
5. Cathepsins [100] Affects immune response 
Affects migration of cancer cells 
6. EGF [101] Indicates poor prognosis 
Involved in cancer cell migration and  
7. Rho GTPases [102] Adhesion of cancer cells to ECM 
Over expressed in certain malignancies 
Implicated in metastasis 
8. VEGF [103] Implicated in tumor invasion, growth and 
vascularisation 
 26 
2.2.2.2 In vivo Studies of the components of cancer microenvironment 
 For a macroscopic view of the ECM remodeling process, we need to 
turn to 3 dimensional models and animal models. Cancer animal models have been 
used for preclinical therapeutics studies and in understanding the effect of certain 
molecules on overall tumor development. Traditionally the tumor size changes are 
monitored over a period of time and the animals are sacrificed for histopathology 
studies. H&E stains and micro vessel count are performed. The tissue samples are 
sometimes further processed to study protein and mRNA expression. Most of these 
studies do not provide spatial information of host- tumor interaction. With the advent 
of fluorescently labeled cancer cells, skin flap models and dorsal skin fold chamber 
models; whole animal imaging has taken a lead role in answering critical questions in 
cancer progression. This method provides us with spatial information not obtainable 
in biochemical studies. 
Whole animal Imaging 
 On comparing several existing methods of imaging, optical imaging has the 
following advantages 
1. Long term labeling: the cancer cells can be transfected with fluorescent proteins, 
which are expressed as long as the cell survives 
2. Resolution: using skin flap models and non-linear optics, features like cells and 
ECM can be distinguished clearly 
3. Real time: The duration of imaging is very short compared to MRI and CT, which 
enable us to observe cellular events 
 Several fluorescent proteins are available for transfection. One among them is 
the Red fluorescent protein (RFP). The advantages of RFP over other fluorescent 
protein are that they have longer wavelength excitation (558nm) and emission (583 
nm). This improves the penetration depth of the signal and enables deep tissue 
 27 
imaging. Secondly their excitation and emission are well away from the auto 
fluorescence signals from the animal body, which are usually in the shorter 
wavelength range. 
 
2.3 SHG as a tool to study cancer microenvironment 
2.3.1 The theory and advantages of SHG 
 Recent work has demonstrated the application of imaging for studying ECM 
changes in in-vitro and in vivo models [34, 104]. We are employing Second 
Harmonic Generation (SHG) imaging to visualize ECM distribution from tissue 
samples. SHG can be used to visualize many biological structures that do not have 
central symmetry (surface materials, chiral materials). Collagen type 1 present in 
ECM is one such molecule that has noncentrosymmetry and hence generate second 
harmonic signals [105-106].  
SHG imaging is usually performed along with two – photon excited 
fluorescence (TPEF) imaging, since both of them share the same laser source. TPEF 
can be used to visualize tissue and cellular architecture without extraneous staining 
just by making use of the auto florescence generated by certain biological molecules 
[107]. The excitation wavelength range for SHG is usually 700-900nm. Since the 
excitation wavelength is near infrared, the scattering is reduced and hence the 
increased depth of imaging. Moreover since the excitation energy is delivered to the 
sample in short pulses the average energy transferred to the sample is low. Hence 
tissue damage or photo bleaching is greatly reduced.  
This technique can be used to study molecular adsorption, aggregation and 
orientation [105]. Prior work using SHG has been helpful in providing information of 
oral malignancy using non-invasive methods in hamster cheek pouch models [108]. 
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The diffusion coefficient of drugs in tumors has been quantified using non-invasive 
means in SCID mice dorsal skin fold chamber models [31]. 
Figure 2a elucidates the concepts of TPEF and SHG. In two-photon 
fluorescence, when the fluorophore absorbs two photons simultaneously, the electrons 
in the fluorophore reach the excited state (Simultaneous absorption of two photons is 
a rare event and hence the source laser needs to generate high density of photons). 
The electron undergoes thermal relaxation and transits to ground state while emitting 
fluorescence. The probability of excitation is related to the square of the intensity of 
the excitation beam. Thus the excited fluorophore is confined to the focal volume. 
This reduces photo damage beyond the focal volume. In second harmonic generation, 
the excitation and emission signal has to be phase matched to obtain maximum output 
signal. In this process there is no absorption of the excitation photon to emit an output 
signal. Hence there is no excited state. Rather it is the property of the material to 





Figure 6: Energy level diagram for Two-photon excited fluorescence and Second Harmonic 
Generation. 
(a) depicts two-photon fluorescence. The dotted line is the virtual state. (b) depicts SHG. (blue 
arrow) is half the wavelength as the excitation signal (red arrow). (c) depicts one photon 
excitation where there is no in-built confocality and all the fluorophores in the beam path is 
excited unless a pinhole is used. (d) shows two photon or SHG excitation where the excitation 
volume is restricted and thus reduces photobleaching and photo damage. The emitted SHG 
signal has certain directionality while the 2-photon emission (2PE) fluorescence is anisotropic 
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SHG has its unique advantages compared to other imaging modalities.  
 SHG signals are generated due to the intrinsic structure and do not need any 
additional labeling such as dyes or fluorescent proteins. 
 The incident signal is a very short, high energy pulse in the order of femto 
seconds impinging on the sample. This causes minimal damage to the sample.  
 The signal to noise ratio is better in SHG compared to conventional systems 
such as florescence imaging. 
 The known excitation and SHG emission spectral signatures, allows easy 
separation of signals from collagen and other fluorophores [31]. 
 SHG provides intrinsic confocality and deep tissue sectioning in complex 
tissue structures [109]. 
2.3.2 Limitations of SHG microscope – Group Velocity Dispersion 
There are several advantages of using the SHG microscope to observe non-centro 
symmetric molecules as described above. But as with all ultra fast laser set-ups, the 
SHG microscope also suffers from Group Velocity Dispersion (GVD). As the term 
suggest, GVD is a dispersion of light on passing through dispersive optical 
components such as lenses, gratings and prisms, where the light is stretched 
temporally. Thus an ultra fast laser whose temporal profile is a Gaussian of 50fs will 
be stretched to a larger time profile. The dispersive components slow down the light 




Figure 7: Group velocity dispersion of a femto-second pulse 
Group Velocity dispersion: A 50 fs laser pulse passing through a dispersive optical component 
(depicted here as a blue rectangle) experiences a positive group velocity dispersion, where the 





Group velocity is defined as the velocity at which the energy of the wave is carried. It 
is the derivative of the wave number with respect to angular frequency. It is related to 
phase velocity as follows, 
                 
Where C is the velocity of light in free space 3 x 10
8
 m/s, n is the refractive index of 
the traveling medium and λ is the wavelength of light in vacuum. 
Group velocity dispersion can be compensated using GVD compensators. There are 
various dispersion compensators like the Chirped mirrors (Fig 10a), pulse 
compressors (Fig 10b) and negative dispersion gratings. Chirped mirrors in 
combination with photonic chirped crystal fibers have been used to generate sub 20 fs 
pulses [110]. These dispersion reversal tools are called pulse compressors or pulse 
modulators. The basic principle pulse modulation is to ensure that low frequency 
signals travel a longer path compared to the high frequency signal, such that all 
frequency components of the resultant wave reaches the sample in a narrow time 
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frame, usually in femtoseconds. To better enunciate this point, a Ti-Sapphire laser 
with a 700-900nm wavelength range and pulse duration of 70-100 fs, can be distorted 
to around 370 fs if the material dispersion is around 13,000 fs2. By placing a pulse 
compressor or compensator, the pulse duration can be readjusted to 100fs. 
 
Figure 8: Reversing group velocity dispersion using pulse modulators such as chirped mirrors 
and paired prisms 
 (a) Chirped mirror – a stack of dielectric mirror in which the light of longer wavelength (red) 
travel deeper before it is reflected while the shorter wavelength (green, blue) light is reflected 
faster, hence compensating for the negative dispersion. (b) Prism based pulse compressor – a pair 
of prism spatially arranged in such a way that longer wavelength light (red) travels a longer path 
compared to the shorter wavelength (blue, green and yellow). 
 
2.3.3 Advantages of using improved SHG to study basic biological processes 
Clinicians and medical scientists are always looking for quantifiable 
information as it is easy to assess the severity of a condition as systematically as 
possible. SHG is an excellent tool for imaging collagen as the information obtained is 
immediately quantifiable. But to ensure the accuracy of the system, we need to ensure 
that the signal to noise ratio and sensitivity of the system is optimal to even pick up 
the smallest of collagen fibers. Pulse modulation ensures highest sensitivity and SNR 
achievable so that the information we obtain is quantifiable and accurate. 
We have chosen collagen as our stroma molecule of interest to study cancer 
ECM interaction for the following two reasons. One – collagen is the most abundant 
biomolecule and cancer cells interact with collagen, remodeling it through matrix 
metalloproteinases. Two – we have an optimized imaging tool to quantify and study 
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collagen with no staining or tissue processing required. 
2.4 Rationale for the proposed study 
2.4.1. Studying the tumor microenvironment in relation to tumor progression 
and chemotherapy  
 
Optical whole animal imaging and SHG imaging have been used to study 
tumor properties before, but to our knowledge we have not seen correlative studies of 
ECM remodeling with tumor progression. It is also not known if the ECM distribution 
varies with drug administration. In this work, with an improved SHG tool, we hope to 
monitor the collagen changes during tumor progression as well as during drug 
administration. The dynamics of ECM with tumor progression and drug 
administration can be used in pre-clinical drug studies to characterize the efficacy of 
the drug and quantify its effects both on the cancer as well as the host environment. 
 
2.4.2. CIC’s role in tumor development and its relationship to the 
microenvironment 
 
 Faster pace of drug discovery and drug testing has expedited the process of 
validating the drugs for human use. The five-year survival rate in case of breast 
cancer patients has improved to about 98% with the plethora of treatments. 
Nonetheless studies have demonstrated loco regional recurrences and distant 
metastases in 49% and 35% of the high risk breast cancer patients studied [111]. 
These information strongly point to the fact that current therapies might not be 
effective to target the CIC.  
Current studies on CIC are more focused on its isolation and in vitro 
characterization. By isolating the CIC and establishing cancer animal models using 
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CIC and non-CIC we can compare growth rates, morphological differences, 
vasculature and metastatic characteristics. This information will enable us to elucidate 
CIC’s role in tumor formation more clearly. The tissue samples obtained from the 
tumor can be used to study the tumor ECM interaction using SHG and TPEF. This 
information will help us compare the ECM remodeling capability of the CIC and non-
CIC cells. Image analysis techniques can be used to identify collagen signatures 
unique to CIC which might help predict patient treatment regimen or prognosis 
 
2.4.3. Improvement of current histopathological analysis 
 
Histopathology studies are routinely done on patient tumor samples. The 
tumor sample is stained using Hematoxylin and Eosin usually to reveal cancer cells 
and surrounding cells. The information obtained from these studies is usually the type, 
grade, receptor status and prognosis of the patient. Along with the usual analysis, 
SHG microscopy of the sample will provide valuable information on ECM 
distribution in and around the tumor regions. We can identify unique collagen 
remodeling patterns in the biopsy samples indicating presence or absence of CIC. 
This information can help clinicians to decide on treatment regimens as well as used 




III Isolation and Characterization of CIC in MX-1 GFP breast 
carcinoma cell line 
3.1 Introduction 
Breast cancer initiating cells (BCIC) has been isolated using several techniques and 
characterised quite extensively both in vitro and in vivo. In a study with the cell line 
MCF7, Ponti et al demonstrated that CIC can grow in suspension culture just like 
normal stem cells do. They called them mammospheres drawing parallels to 
neurospheres technique of neural stem cell culture. These cells escaped the process of 
Anoikis, which is cell death in the absence of adhesion. The mammospheres were 
shown to have differentiation potential and tumorigenicity in animal models. The 
tumors initiated by mammospheres had higher levels of VEGF expression [17]. 
Al Hajj and his colleagues utilised the differential expression levels of CD44 and 
CD24 on breast cancer cell lines and primary patient samples to isolate CIC, however 





 cells engrafted in animals in much smaller numbers compared 
to the bulk population. The histology also demonstrated that the tumors formed by 
CD24
-
 had malignant cells, while the site of injection of CD24
+
 cells resembled 









 population [47]. 
The side population method has been used to isolate stem cells from the 
hematopoietic system utilising the property of stem cells to efflux lipophilic dyes 
more than the differentiated cells. This technique has been successfully demonstrated 
in isolating CIC in several cancer studies [15, 54, 64, 112-113].  
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We wanted to demonstrate that side population method can be used to isolate the CIC 
from an invasive breast cancer cell line MX-1. We have performed in-vitro 
characterization of CIC vs. non CIC such as testing for its proliferative capacity, drug 
resistance and CD44/CD24 marker expression analysis, invasiveness and migration 
potential to ascertain that the side population we are isolating have the phenotypes of 
cancer initiating cells that are reported in prior literature. We have injected the 
isolated CIC and non-CIC in immune-compromised mice to study their 
tumorigenesis. After developing the animal models we have observed differential 
tumor growth and vascularization in the case of tumors formed by CIC compared to 
those of non CIC tumor. This implies that there are inherent differences between CIC 
and non CIC tumorigenicity, growth and invasion. All our experiments demonstrate 
that isolating CIC from GFP labelled MX-1 cells using the side Population technique 
is a suitable model to study CIC in-vitro and in-vivo. This model has been established 
for studying the ECM remodelling properties of CIC in-vivo which is discussed in 










3.2. Materials and Methods 
3.2.1 Side Population Analysis, Cancer Initiating Cells Isolation and Cell 
Proliferation Assay 
GFP labelled breast cancer cell line MX-1 was used for all the experiments. MX-1 
cells were cultured in RPMI medium with 10% fetal calf serum (FCS), 1.5 g/L 
Sodium Pyruvate, Sodium Bicarbonate and Penicillin Streptomycin. Cells were split 
every 3 days when they were 80% confluent. 
For side population analysis, cells were trypsinized, spun down and 1 million cells 
were resuspended in 1 mL RPMI medium with 2% FCS and 10 mM Hepes Buffer. 
5ug/mL Hoechst 33342 dye was added and the cell suspension was placed in a 37 
degrees water bath for 2 hrs. For blocking the cells from effluxing the dye the 
transporters can be deactivated using the drug verapamil (Sigma Cat No:V4629). 10 
ug/mL of verapamil was added to the cell suspension during the 2 hr, 37 degrees 
incubation.  
For the time profile analysis the cell suspension was incubated for 0.5, 1, 1.5, 2, 2.5 
and 3hrs. The cell suspension was agitated to prevent the cells from settling down and 
to enable uniform dye distribution.  After 2 hrs the cells were spun down in a 
centrifuge pre-cooled to 4 degrees. The cell pellet was resuspended in a chilled HBSS 
buffer with 2% FCS and 10 uM Hepes Buffer at a concentration of 3 million cells/mL. 
The temperature has to be maintained below 4 degrees at all times to prevent further 
dye leakage from the cells. 
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A BD fluorescence activated cell sorter (FACS) FACSAria was used to analyse for 
side population and sort for cancer initiating cells. A UV laser was used to excite the 
cells and emission at 450/20nm (blue) and 675 nm (red) were recorded. When the 
cells retain the dye in the cell interior a blue fluorescence can be detected. As time 
progresses the dye enters the nucleus where they bind to the DNA and produce red 
fluorescence. The side population or cancer initiating cells those are capable of 
pumping the Hoechst 33342 dye show up low on both blue and red fluorescence. Both 
the CIC and non CIC were collected in culture medium with antibiotics and 
antimycotic drugs added. For analysis data points from 100,000 cells were collected. 
After sorting, 20,000 cells were plated in 24-well plate and monitored for 
contamination. After ensuring proper cell proliferation, light images were acquired 
using Olympus IX51 light microscope one week after sorting. The cells were cultured 
and maintained over five passages and cell numbers were counted. The experiment 
was performed twice in triplicates. 
 
3.2.2 Flow cytometric Analysis for Chemotherapy drug efflux 
To study the side population profile for short term drug treatment, the cells were 
incubated with Hoechst 33342 and 200 ng/mL doxorubicin or mitoxantrone for the 
first 1 hr of the 37 degrees incubation. The cells were spun down in a 37 degrees 
centrifuge and resuspended in RPMI medium containing the Hoechst dye alone and 
incubated for another hour. To study the side population profile for long term drug 
treated cells, MX-1 were cultured with 50 ng/mL doxorubicin or mitoxantrone for 7 
days and then stained with Hoechst 33342 and analysed by flow cytometry. 
Doxorubicin can be excited at 488 nm and emitted fluorescence was detected at 
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565/50 nm. Mitoxantrone can be excited at 633 nm and emitted fluorescence detected 
at 670/40 nm. 
 
3.2.3 Colony Formation Assay and imaging of drug treated cells 
1000 CIC and non CIC were plated on 48 well plates and 50 ng/mL doxorubicin or 
Mitoxantrone was added to the culture medium. The cells were treated with the drugs 
for 7 days. The cells were cultured in medium alone for another 7 days before the 
colonies were counted. A colony was considered to at least have 10 cells.  
After sorting CIC and non CIC, 10,000 cells were cultured in 8 well Labtek Chambers 
(Nunc, Cat No. 155411) for 3 days. 200 ng/mL doxorubicin or Mitoxantrone was 
added to the culture medium and incubated at 37 degrees for two hours. The cells 
were then washed with 1X PBS and fixed using 3.6% Paraformaldehyde and imaged 
using a Laser scanning confocal microscope. Doxorubicin was excited using a 488nm 
Argon laser and the emitted fluorescence detected using a 565-615 band pass filter.  
3.2.4 Migration and Invasion Assay 
50,000 isolated CIC and non-CIC cells were seeded on cell culture inserts (Cat No. 
353097, Falcon, BD Biosciences, San Jose, CA) for migration assay and on cell 
culture inserts coated with Matrigel (Cat No.354277, BD Biosciences, San Jose, CA) 
for invasion assay. Cells were cultured with 1% Fetal Calf serum (FCS) containing 
media on the upper well and 20% FCS containing media in the lower well acted as the 
chemo-attractant. Cells were cultured in humidified 37ºC, 5% CO2 incubator for 24 
hrs. After which the cells or cells and Matrigel was removed using cotton swabs and 
the lower surface of the cell culture inserts was stained using crystal violet and the 
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number of migrated  or invaded cells were counted using a light microscope (IX 51, 
Olympus Corporation, Japan) using a 20X objective. Cells in three fields of view per 
insert were counted and the average per insert was calculated. For each migration and 
invasion condition three replicates were performed. 
3.2.5 CD44 and CD24 expression analysis of CIC and non-CIC 
For CD44 and CD24 expression analysis, anti-human CD44 and CD24 antibodies 
tagged with PE (BD, Pharmingen Cat No: 550989, 555426) was added to the chilled 
cell suspension after Hoechst staining and allowed to stain for 15 mins. The cells were 
washed in 1X Phosphate buffered saline (PBS) thrice and resuspended in HBSS 
buffer. The cells were analyzed in a FACS machine (FACS Aria, BD). The cells were 
excited by UV (305 nm) as well as Argon (488 nm) lasers and the emission is 
collected using 450±50 nm and 585±20 nm band pass filters for the Hoechst and PE 
fluorescence respectively. 100,000 data points are collected and the percentage of CIC 
and non-CIC cells positive for CD44 or CD24 are analyzed using BD FACS Diva 
software. 
3.2.6 Developing CIC animal models and in vivo imaging 
Isolated CIC and non CIC were cultured for 2 days to allow them to recover from the 
stress of sorting before administration to animals. On the day of injection, 100,000 
CIC and 1 million non CIC were trypsinised, counted, spun down and resuspended in 
200 uL of chilled 1X PBS. The cell suspension was injected subcutaneously in the 
right flank of SCID mice. Sorting, cell culture and injection was done for consecutive 
four weeks to have four CIC and four non CIC SCID mouse model. Animals were 
anesthetised and shaved to image using the in vivo live imaging system (OV100, 
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Olympus Corporation). Images were taken once at 4 weeks after injection and then 8 
weeks after injection.  
3.2.7 Histology 
Haematoxylin and Eosin (H&E) staining was carried out using standard protocol. 
Briefly tissue sections were fixed in ethanol and stained in Ham’s Haematoxylin for 
two minutes, washed thoroughly, checked for good staining and stained in Eosin for a 
few seconds. The stained sections are dehydrated in ethanol and Xylene and mounted 





3.3.1 CIC can be isolated from the invasive breast cancer cell line MX-1 
The side population analysis technique was established by Dr.Goodell’s lab to study 
the stem cell populations in the hematopoietic system [114]. Stem cells possess the 
property to efflux administered dyes through molecular pumps and hence will appear 
to have low fluorescence when analysed in flow cytometry. Hoechst 33342 is a 
nuclear dye which emits blue fluorescence (Hoechst blue) as long as it is in the 
cytoplasm and red fluorescence (Hoechst red) when the dye binds to the DNA. Thus 
the stem cells will be low in both blue and red fluorescence and emerge as a tail like 
population in the lower quadrant of a flow cytometric experiment. The cells which lie 
along the x axis are the debris and dead cells. To ensure that the technique is suitable 
for isolating CIC from the MX-1 cell line, we tried out a time series of incubation of 
the cells with Hoechst 33342 (Fig 9a). After 0.5 hr and 1hr of staining, majority of the 
cells have taken up the dye but are still low in Hoechst blue fluorescence. After 1.5 
hrs and 2hrs of staining the tail percentage drops to about 0.28%. This could be due to 
the beginning of effluxing action where the side population cells are getting stained 
and they are trying to pump the dye out, while the majority of the cells are unable to 
efflux the dye. At the 2.5 hr and 3hr time point the nucleus have been stained which 
can be seen by their elevated position along both x and y axis. The percentage of cells 
with low blue and red fluorescence has dropped to about 0.13%. These cells will be 
collected as the side population. The 2.5 hr long incubation was used for all 
experiments. The CIC percentage varied between 0.1% and 0.3% in our experiments. 
The 3 hr incubation period was not used as the number of dead cells increased (data 
not shown).  
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The CIC have been attributed to efflux the dye due to the enhanced function of drug 
efflux pumps such as the Multiple Drug Resistance (MDR) proteins, P-glycoprotein 
and ATP binding cassette (ABC) family transporters such as ABCG2 and ABCC1. 
These pumps can be ubiquitously blocked using drugs such as verapamil, cyclosporin 
and Fumitremorgin C. We used verapamil to block the drug transporters to ensure that 
the CIC population are low in dye concentration due to the effluxing functions of 
these pumps. On adding verapamil, the CIC population was almost abolished (less 15 




Figure 9: Cancer Initiating Cells can be isolated from MX-1 using side Population method 
MX-1 cells stained with Hoechst 33342 were analyzed for the stain levels every half hour from 0.5 
hr to 3hr time point. The cells equilibrated at 2.5hr time point where the majority G0-G1-S 
population was saturated with the dye. The 2.5 hr incubation was used for all cancer initiating 
cells isolation (a). Verampil a channel blocker is used to block the pumps on the cell surface 
preventing the cells from effluxing the dye, confirming that CIC is a population with dye 
effluxing properties (b, c). 
 
3.3.2 CIC shows less differentiated morphology, better proliferative capacity and 
higher CD44 expression 
As the Hoechst dye is toxic in high concentrations the cells do not proliferate as fast 
as pre-sorting. The plated cells take about a week to form colonies in the case of CIC 
(Fig 10a). The non CIC cells also proliferate but they do not have clone like 
appearance (Fig 10b). The less differentiated cells or precursor cells when seeded as 
single cells can repeatedly proliferate to form tight colonies while the more 
differentiated cells do proliferate but have a flat and spread out morphology. This 
could also indicate that the CIC are less attached to the substratum while the non CIC 
is well attached to the substratum.  
To examine the proliferation capacity of these cells we tracked the cell count over 
several passages with an initial seeding count of 20,000 cells. The CIC were able to 
proliferate at a higher rate to yield 33 million cells in five passages, while the non CIC 
was able to yield 11.5 million cells (Fig 10c). The difference in proliferation in the 
first passage was more drastic where the CIC proliferated to produce 2 million cells 




Figure 10: CIC morphology and their proliferation properties 
Light micrographs of CIC and non CIC in culture, 7 days after isolation show that CIC forms 
colonies with more 3D appearance (a) while the non CIC are more spread out and well attached 
to the substratum (b). The top two panels show images taken with a 20X objective and the 
bottom two are magnified images with a 40X objective. CIC population generates both CIC and 
non CIC as it proliferates. The proliferation rate of this population is higher than that of non-
CIC alone (c). Scale bars 20μm in (a) and (b) 
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3.3.3 CIC survives better under chemotherapeutic treatment regimens of 
doxorubicin and mitoxantrone due to their superior drug effluxing capability  
We demonstrate the improved drug resistance of CIC using a short term 2 hr and long 
term 7 days drug exposure followed by staining and analysing for CIC. Due to the 
short term drug exposure the percentage of CIC does not change significantly while 
the non CIC population seems disrupted in the case of doxorubicin and mitoxantrone 
(Fig 11a, 12a). After 7 days of drug exposure, the non CIC population is virtually 
eliminated in case of doxorubicin and reduced considerably in the mitoxantrone 
treatment. The CIC population now constitutes about 26% of the sorted cells (Fig 11b, 
12b). This increase may be due to the proliferation of CIC in culture or due to the 
sensitization of the drug transporters enabling them to efficiently pump out more dye. 
As both the drugs emit fluorescence, the drug concentration in CIC and non CIC 
populations were recorded using appropriate filters. The CIC cells had lower 
mitoxantrone concentration than the non CIC cells (Fig 12d). We were unable to 
visualise any changes in doxorubicin concentration in the flow cytometry experiment.  
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Figure 11: CIC is more resistant to Doxorubicin treatment 
MX-1 cells were treated with doxorubicin either for 2 hrs or 7 days and stained with Hoechst and 
analyzed to observe the changes in the CIC and non CIC population.(a)  The top two panels show 
that after short term treatment the CIC percentage remains constant while the non-CIC 
population is disrupted (a). The bottom two panels show that after long term treatment the non-
CIC population is almost abolished (b). Colony formation assay was performed with sorted CIC 
and non CIC to observe that CIC forms four time more colonies than non-CIC in the presence of 
50 ng/mL doxorubicin (c). Fluorescence confocal microscope images of CIC (left) and non-CIC 
(right) cells after two hours treatment with doxorubicin show that non-CIC distinctly 









3.3.4 Isolated CIC forms more colonies in the presence of the drugs doxorubicin 
and mitoxantrone and show lower drug accumulation in fluorescence imaging 
The sorted CIC when cultured in the presence of doxorubicin or mitoxantrone are able 
to form more colonies (Fig 11c, 12c). In the absence of drugs, CIC are able to form 
about 395 colonies for every 1000 cells seeded while non CIC forms 177 colonies. In 
the presence of 50 ng/mL doxorubicin the number of CIC colonies drops to 16 while 
the non CIC can form 3 colonies and in 50 ng/mL of mitoxantrone the CIC forms 18 
colonies while the non CIC forms 3 colonies. 4% and 4.5% of the CIC colonies 
survive the doxorubicin and mitoxantrone treatment, while 1% of the non-CIC 
survives the treatments. In this experiment, colonies with at least three or more 
surviving cells were counted as surviving colonies. The single cells that were in the 
tissue culture plate were not counted. The colonies formed by CIC by dividing are not 
all CIC. Thus the number of surviving CIC could have been underestimated.   
We observed the drug accumulation in CIC and non CIC colonies after two hours of 
doxorubicin treatment (Fig 11d) and mitoxantrone treatment (data not shown). 
Distinct spots of drug accumulation were observed in non CIC, compared to the 








Figure 12: CIC is more resistant to Mitoxantrone treatment 
MX-1 cells were treated with mitoxantrone (+Mito) either for 2 hrs or 7 days and stained with 
Hoechst and analyzed to observe the changes in the CIC and non CIC population compared to 
the untreated samples (-Mito) .(a)  The top two panels show that after short term treatment the 
CIC percentage remains constant while the non-CIC population is disrupted (a). The bottom two 
panels show that after long term treatment the non-CIC population is almost abolished (b). 
Colony formation assay was performed with sorted CIC and non CIC allowed to reach about 
colonies of 10 cells and then treated with 50 ng/ml of mitoxantrone to observe the number of CIC 
colonies surviving compared to the non-CIC colonies. Six times more CIC colonies can survive in 
the presence of 50 ng/mL mitoxantrone than non-CIC colonies (c). MX-1 cells were incubated 
with Hoechst stain along with mitoxantrone and the fluorescence data at 633nm of mitoxantrone 
was collected from the CIC and non-CIC population during flow analysis to conclude that non-










Figure 13: CD44 expression in CIC and non-CIC. 
CD44 expression assessed on CIC and non-CIC revealed that CIC expresses two folds higher level of 
CD44 than non-CIC and both CIC and non-CIC had ten folds higher expression of CD44 than the 
negative control. 
 
3.3.5 CIC have higher expression of CD44 and is more invasive and migratory 
compared to non-CIC  
When the CD44 expression level of CIC and non-CIC was compared, it was found 
that CIC expressed two folds higher CD44 compared to non-CIC (Fig 13). The CD44 
high phenotype of CIC isolated using side population method correlates with CIC 
isolated using marker expression. 
In in-vitro assays, using transwell chambers, the CIC is found to be more migratory 
and more invasive than non-CIC. CIC had at least two fold higher migration potential 
across the membrane towards a chemoattractant. The number of CIC invading across 
an ECM matrix towards a chemoattractant was also found to be significantly higher 















Figure 14: CIC is more invasive and migratory in vitro and more tumorigenic in vivo than non-
CIC 
(a)Boyden chamber assay comparing the migratory and invasive potential of CIC and non-CIC 
showed that CIC was at least two folds more migratory and invasive than non-CIC (*: t test: 
p<0.05). The grey bars depict CIC while the black bars depict non-CIC. Whole animal imaging 
system was used to image the GFP labelled tumours in-vivo. After 8 weeks, visible tumours were 
observed in all the CIC injected animals of which one is shown here (b), and only one non-CIC 
injected animal (c). The CIC tumors were bigger than the non-CIC tumor. Blood vessels were 
visualised in the CIC tumor but not in the non-CIC tumor. The H&E images of CIC (d) and non-
CIC (e) shown are acquired using a light microscope with a 10X objective. The tumor interior 
(TI) and tumor boundary (TB) are shown for both the CIC and non-CIC tumor. The bright light 
CIC (f) and non-CIC (g) tumor images are also shown. Scale bar 1mm in (b) and (c) and 50μm in 
(d) and (e), 10 mm in (f) and (g) 
 
3.3.6 CIC is more tumorigenic in SCID mice models than non CIC 
Tumorigenicity in animal models in small numbers has been considered hallmark of 
cancer initiating cells. In in-vivo experiments where 100,000 CIC and 10 million non-
CIC were injected into animals, tumor growth was observed using a whole animal 
imaging system (OV100, Olympus Corporation, Japan). Despite injecting hundred 
folds more non-CIC than CIC, all five animals injected with CIC formed tumors while 
only one animal with non CIC formed a tumor in 8 weeks time. The representative 
fluorescence images of the CIC and non-CIC tumors are shown in Fig 14b and 14c. 
The fluorescence intensity and area has been quantified and it was found to be at least 
three times higher in CIC compared to non-CIC. H&E stains are shown in Fig 14d 
and 14e. The H&E stains showed well-developed tumor encapsulated by surrounding 
tissue in all five CIC tumors and one non-CIC tumor. Histological examination of the 
other four non-CIC tissues showed no tumor cell implantation. 
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3.4. Discussion 
The side population analysis technique was established in Dr.Goodell’s lab to study 
the stem cell populations in the hematopoietic system [114]. The CIC have been 
attributed to efflux the dye due to the enhanced function of drug efflux pumps such as 
the Multiple Drug Resistance (MDR) proteins, P-glycoprotein and ATP binding 
cassette (ABC) family transporters such as ABCG2 and ABCC1. These pumps can be 
ubiquitously blocked using drugs such as verapamil, cyclosporin and Fumitremorgin 
C. The mammosphere culture technique, in which the CIC’s property to be able to 
sustain in suspension culture and overcome anoikis, has also been used to isolate CIC 
[17]. Certain markers for stemness and surface markers such as CD44, CD133 have 
also been used to isolate CIC [11]. In our study we have been able to isolate CIC from 
MX-1 cell line successfully using the side population technique and the drug 
verapamil abolished the population proving the role of the molecular pumps in side 
population. We also tried the suspension culture but were unable to create a 
mammosphere culture. Along with performing the side population analysis we also 
immunostained the cells for CD44 and found that the CIC was CD44
high
.   
We explored the difference in proliferation of the CIC and non-CIC after sorting. The 
difference in proliferation in the first passage was more drastic where the CIC 
proliferated to produce 2 million cells compared to the 320,000 cells of non CIC. This 
difference cannot be only attributed to the Hoechst retention by the non CIC as the 
drugs are cleared by the cells in 2 to 3 days and we do not observe proliferation of 
either CIC or non CIC 2-3 days post sorting. We believe that this higher proliferation 
of CIC is not because they generate more CIC, instead they divide to generate non 
CIC, because on reanalysis of the proliferated cells, they recapitulate the entire 
population consisting of both CIC and non-CIC cells. The ability of CIC cells to 
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proliferate to generate the entire population has also been demonstrated as the 
hallmark of CIC [15]. The non CIC cohort alone might not be able to sustain 
themselves in the absence of CIC and hence unable to proliferate as fast as the CIC 
cohort. The CIC are shown to proliferate more and form small tight colonies in 
ovarian cancers as well [63] while in nasopharangeal cancer the CIC lost its 
characteristic as differentiated squamous epithelial cell and appeared more like 
fibroblasts [115].  
Drug resistance is one of the hallmarks of cancer relapse where a few cancer cells can 
evade the treatment and go on to establish tumors at the primary site or metastasize to 
other organs. CIC have shown that these cells are more radiation resistant and chemo-
resistant than the bulk of the cells [116-118]. We used two commonly used 
chemotherapeutic drugs doxorubicin and mitoxantrone to determine the drug 
resistance profiles of CIC. Doxorubicin is an anthracycline antibiotic, DNA 
intercalating agent used for the treatment of leukaemia, lymphomas, several epithelial 
cancers, sarcomas and myelomas. Mitoxantrone is an anthracenedione, topoisomerase 
II inhibitor which prevents DNA synthesis and repair. It is used in the treatment of 
metastatic breast cancers, non Hodgkin’s lymphoma and acute myeloid leukaemia  
(AML). There have been some studies to test the resistance of the CIC to 
chemotherapeutic agents such as paclitaxel, doxorubicin and mitoxantrone [63]. There 
is a marked inhibition of non-CIC cells by these chemotherapeutic agents compared to 
CIC. We studied both the short term and long term chemoresistance of these cells to 
doxorubicin and mitoxantrone.  Within 24 hours the changes in CIC is not visible but 
the non-CIC population seems disrupted. In the long term study, there is a marked 
increase of CIC cells being able to survive 7 days of chemotherapy. This increase of 
CIC may be due to the proliferation of CIC in culture even in the presence of 
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doxorubicin or mitoxantrone, or due to the sensitization of the drug transporters 
enabling them to efficiently pump out more drugs. It is thus shown that these broad 
spectrum chemotherapeutic agents are unable to interfere with the DNA in the CIC 
population and prevent its proliferation. There has been an effort to show that 
recombinant erythropoietin and oncolytic adenoviruses can be used as an approach to 
target CIC [119-120]. Certain pathways including that of NF-Kappa-B [Liu].  Wnt 
[Lindvall] , Notch [Farnie] are being implicated in CIC progression. These pathways 
are involved in normal stem cell development as well. The challenge is to be able to 
identify unique features or pathways in CIC to target them to eradicate these cells 
[Zhou J 2008]. 
Tumorigenicity in animal models in small numbers has been considered hallmark of 
cancer initiating cells. This has been shown in several studies [Ponti, Hirschmann, 
szotek, chiba]. When we injected 100,000 CIC cells and 10 million non-CIC cells into 
the animals, all CIC injected animals developed tumors, but only one non-CIC 
injected animal formed a tumor. In an ovarian cancer study they demonstrated that the 
non-CIC population was able to form a tumor only because there was a contamination 
of the non-CIC with some CIC cells [63]. In our study we did not isolate live tumor 
tissue to perform this experiment.  In our experimental set up we tried to inject fewer 
CIC cells such as 1000 cells and 10,000 cells into the animal. We were unable to 
visualize any pellet of cells after centrifugation of the sorted cells. Thus to ensure that 
the sorted cells were spun down properly to be in the 200 µl injection volume was not 
possible. Hence we decided to perform the final comparison experiment with 100,000 
CIC and 10 million non-CIC.  The tumors in the CIC cohort showed well developed 
structure with blood vessels seen in the whole animal imaging system. The only tumor 
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in the non-CIC cohort was poorly developed and it was barely visible under the 
animal’s skin.  
3.5. Conclusions 
We have demonstrated that CIC can be isolated from an invasive breast cancer cell 
line MX-1. The CIC isolated from MX-1 have a higher proliferative capacity than the 
non-CIC. The CIC can proliferate and generate both CIC and non-CIC after a few 
passages. CIC is more resistant to chemotherapy administrations such as doxorubicin 
and mitoxantrone. They survive both short and long term exposure of the drugs, 
efflux the drug efficiently and are able to form more colonies in the presence of these 
drugs in culture. In xenograft models, the CIC established tumors in all five mice 
administered with 100,00 CIC while only one out of the five mice formed a tumor 
when injected with 10 million non-CIC. Thus CIC can form tumors with 10 fold less 
cells compared to non-CIC. Whole animal imaging revealed that tumors formed by 
CIC were larger and more vascularised compared to the one formed by non-CIC. 
Thus we have established a CIC isolation and characterization strategy for the breast 
cancer cell line MX-1 using side population analysis method. The CIC and non-CIC 
tumors obtained from these xenograft models will be used for studying the CIC-ECM 
interactions in-vivo using the SHG imaging system. As discussed in section 2.3, 
current SHG systems are limited by GVD. In chapter IV we describe how we improve 
the SHG system by reversing GVD. The CIC-ECM interactions will be studied using 





IV Development of SHG microscope with Pulse modulation (PM-
SHIM) and validating the PM-SHIM using chemotherapy studies 
1. Introduction  
Cancer is a disease where a series of mutations accumulate in normal cells, with 
increased resistance to cell death or apoptosis followed by uncontrolled cell division. 
The cancer cells need the host-derived cells like the endothelial cells and fibroblasts 
for vascularization and support to form a tumor [121]. The host cells help the cancer 
cells by degrading or secreting component of the microenvironment to establish the 
tumor niche. Collagen is one such component that is an important component of this 
tumor niche.  The cancer cells use the collagen fibers for physical support in the 
growing stages and the fibers are remodeled as the tumor mass requires expansion and 
invasion [122-123].  
Second Harmonic Generation (SHG) imaging is suitable to visualize non centro 
symmetric biomolecules such as myosin, collagen type I and IV [124-125]. SHG 
imaging is especially suitable for tumor pathology studies as there are no staining 
process involved and thin tissue sections are not required, making sample preparation 
simple, providing 3D sectioning capability without using confocal pinhole, with 
deeper penetration depth [126-127] [128]. [129-130]. There has been a series of 
articles demonstrating collagen imaging in several tissue types and whole organs in 
in-vitro, animal and human studies [131-135]. SHG imaging of collagen in cancer 
models have been demonstrated in Melanoma, breast cancer, cervical and ovarian 
cancer in animal and human studies [31, 136-140]. But almost all of them have not 
been able to quantitatively visualize collagen patterns in the tumor interior. 
The optical components introduce Group Velocity dispersion (GVD) where the 
longer wavelength light in the pulse travels faster than the shorter wavelength light 
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[141-142]. SHG depends directly on the peak power delivered to the sample. SHG 
and TPEF signals generated from the sample are inversely proportional to the pulse 
duration of the excitation light. Thus GVD increases the pulse duration, reduces the 
peak power of the incident light on the sample affecting the second harmonic and 
TPEF signals generated. Pulse modulators can be introduced in the optical path of the 
microscope to introduce negative chirp that counteracts the positive chirp introduced 
by dispersive optical components [143]. There are a few articles that show the 
improvement in SHG after pulse modulation using biological samples such as human 
skin and mouse kidney [144-145].  
We demonstrate that by using pulse modulated second harmonic imaging 
microscope (PM-SHIM) collagen fibers of all dimensions can be detected and 
quantified. We validate the functionality of this improved system in muscle tissue, 
liver tissue and collagen gels, thereby demonstrating the wide array of applications of 
the PM-SHIM in connective tissue related studies. A key validation of the PM-SHIM 
is done using the ex-vivo tumor samples from xenograft models after chemotherapy. 
There are several studies to demonstrate that collagen acts as a hindrance to drug 
diffusion both in in vivo [31] and in vitro models [146], and by breaking down the 
barrier there can be an improvement in drug delivery [147-148]. On the other hand, 
the tumor stroma has lower collagen content than normal tissue [32]. In that case the 
drug should be able to reach the tumors better. But in solid tumors chemotherapy can 
be initially effective and became ineffective later [149-151]. Gene expression studies 
show that chemotherapy stimulates wound-healing responses in tissues upregulating 
collagen [152-155]. We hypothesize that quantifying the spatial distribution of 
collagen inside tumors will yield a highly sensitive means to directly monitor the 
drug-induced barriers to further efficacy, and become a powerful tool to aid in the 
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development of drug combinations or regimens that remain efficacious to achieve 
complete tumor cell elimination. Understanding the process of collagen remodeling 
inside tumors will require more sophisticated tools for quantification. We have 
demonstrated that the increased sensitivity of PM-SHIM to quantify collagen in tumor 
allowed us to directly test the hypothesis that chemotherapy can increase collagen 
fibers inside tumors to impede further therapeutic efficacy of chemotherapeutic 
agents.  
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2. Materials and Methods 
2.1 The Imaging System 
The light source used is an ultra-fast laser operating at 900 nm with 100 fs pulse 
duration (Mai Tai Titanium Sapphire Laser, Spectraphysics). The imaging was done 
using a confocal microscope (LSM 510 Meta, Carl Zeiss GmbH). Source laser passes 
through the prism based pulse compressor (Femto Control, APE GmbH, Germany) 
followed by the Acousto Optic Modulator (AOM) and is then focused on the sample 
with a 20x objective lens, numerical aperture (NA) =0.5. The SHG signal was 
measured at the other side of the sample, filtered through a 450 nm band pass (BP) 
filter (full-width half-maximum = 10nm) before reaching the photomultiplier tube 
(PMT) (R6357, Hamamatsu Photonics). The schematic of the microscope set up is 
shown in Fig 1a. 
A chirp analyzer (GRating-Eliminated No-nonsense Observation of Ultrafast 
Incident Laser Light E-fields, Swamp Optics) was used for measuring the dispersion 
profile of the laser resulted from pulse compression. The Frequency Resolved Optical 
Gating (FROG) based chirp analyzer measures the spectrum of the laser pulse by 
using a Fresnel Biprism and a thick SHG crystal {Akturk, 2004 #101}. The beam 
profile was measured at three locations: A) before the AOM, B) after the AOM, and 
C) at the sample stage (see Fig 15a). In positions A and B, measurements were made 
by direct interception and feeding the laser to chirp analyzer.  In position C, a mirror 
was placed on the microscope stage and a beam splitter was used such that the 
measurement was taken after laser enters and leaves the microscope under identical 
paths (see Fig 15b). For all positions, pulse duration was optimized by systematically 
adjusting the prism 1 and prism 2 positions inside the pulse compressor. The prism 
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positions were controlled using a stepper motor whose angular positions can be varied 
using a remote control. 
 
 
Figure 14: Schematic of the PM-SHIM set up.  
The set up of the PM-SHIM is shown in the left and the alignment configurations for chirp 
analysis is shown in the right. The PM-SHIM consists of a femtosecond (fs) laser followed by the 
pulse compressor, AOM and the confocal microscope set up. The AOM is used to modulate the 
power delivered to the sample using a diffraction grating. The laser beam reaches the sample and 
the SHG and TPEF signals from the samples pass through a band pass (BP) and short pass (SP) 
filter  in the transmission and reflection mode respectively and the signals are collected using a 
photomultiplier tube (PMT). A, B and C are three positions at which the laser beam is 
characterized using the Chirp analyzer. The laser beam from the femtosecond laser, before the 
AOM (A), after the AOM (B) and at the sample stage (C) are  guided to the chirp analyzer using 
mirrors (M1 –M6) and a beam splitter. The beam splitter (BS) is used to reduce the laser power 





2.2 Xenograft Model, Tissue Isolation and Collagen hydrogel preparation 
Cell Culture: MV4-11 cells were cultured with RPMI1640 (Invitrogen, Carlsbad, CA, 
USA) supplemented with the addition of 10% fetal bovine serum (FBS; JRH 
Bioscience Inc., Lenexa, KS, USA) at a density of 2–10 × 105 cells ml-1 in a humid 
incubator with 5% CO2 at 37 ºC. 
Animals: Female severe combined immunodeficiency mice (17–20 g, 4–6 weeks old) 
were purchased from Animal Resources Centre (Canning Vale, WA, Australia). 
Exponentially growing MV4-11 cells (5×10
6
) were subcutaneously injected into loose 
skin between the shoulder blades and left front leg of recipient mice. All treatment 
was started 25 days after the cell injection; when the mice had palpable tumor of 300–
400mm
3 




 by oral gavage 
daily. ABT-869 was provided by Abbott Laboratories (Chicago, IL, USA). For in 
vivo experiments, ABT-869 was prepared as published previously [156]. The protocol 
was reviewed and approved by Institutional Animal Care and Use Committee in 
compliance with the guidelines on the care and use of animals for scientific purpose 
(IACUC Protocol No.050118).After completion of treatment, animals were 
anesthetized using 90mg Ketamine and 9 mg Xylazine mixture. The skin flap was 
opened; chest cavity was exposed to perform a cardiac perfusion of saline to flush out 
blood and then 4% Paraformaldehyde (PFA) to fix the tissues. The tumors were 
isolated and frozen immediately in liquid nitrogen. Liver and muscle tissues were also 
isolated from other animals. Tissues are sectioned at 40μm, 20μm and 10μm for 
imaging. 
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Collagen hydrogel was prepared by mixing 0.49ml rat tail type I collagen (BD 
Biosciences, San Jose, CA), 100μl Phosphate buffered saline (PBS) and 0.41 ml 0.025 
M Sodium hydroxide to obtain a 4 mgml
-1
, pH 7.4 neutralized collagen solution. 
100μl of the solution was pipetted onto 0.17mm thick coverslip and dried at room 
temperature for 48hrs before imaging. 
2.3 Image Acquisition and Signal to Noise Ratio Analysis  
Conventional SHG images were taken without pulse compression, in which laser by-
passes the pulse compressor prisms and routed directly to the microscope. PM-SHIM 
images were taken when the pulse duration was minimized with optimized pulse 
compression. All samples, including muscle, liver, and collagen hydrogels were 
imaged with both conventional SHIM and PM-SHIM. In all cases, we recorded a 
background image using plain glasses as dark background levels for signal 
processing. We used the 20X objective to obtain 460 μm x 460 μm, 512x512 pixels 
images. Nine such images were stitched to obtain the tile scan image of 1382 μm x 
1382 μm, 1536x1536 pixels images. The tile scan images were used for analysis 
purposes. Signal to background ratio (SBR) was defined as the average pixel intensity 
value of SHG signal to the background intensity acquired earlier from the plain glass. 
SBR of conventional SHIM and PM-SHIM was compared directly by dividing one 
SBR with the other. 
2.4 Image acquisition and quantification of collagen remodeling in tumor 
samples 
PM-SHIM and conventional SHIM images of the tumor sample were acquired as per 
previous settings. An image segmentation algorithm based on mixture Gaussian 
model was performed to remove background and noise. It is assumed that the 
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intensity of pixels in the image can be modeled as the mixture of two Gaussian 
distributions, one representing collagen area with strong SHG signals and the other 
representing the background. Using the Expectation-Maximization (EM) algorithm 
{Dempster, 1977 #229}, the parameters of the Gaussian distributions which model the 
intensity of pixels in the image best could be found. A binary image was generated by 
applying value 1 to all the pixels having intensity which belongs to the Gaussian 
distribution representing collagen area and value 0 to the rest of the pixels.  
We quantified four parameters namely collagen area percentage, fiber number, 
fiber length and fiber width. The percentage of collagen area was determined as the 
number of pixels which are segmented as collagen divided by total number of pixels 
in the same image. The connected component labeling algorithm {Gonzales,  #338} 
was performed on the binary image which groups the connected pixels with value 1 
into one object, while each object represents a collagen fiber or fiber bundle. The fiber 
number was determined as the number of objects in each image. The fiber length was 
calculated as the average length of the long axis of each object in the image, and the 
fiber width was quantified as the average length of the short axis of each object in the 
image. All image processing and algorithm execution were carried out using 
MATLAB (The Math Works, Inc, Natick). Image processing algorithm code is 
available for readers upon request. 
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3. Results and Discussion 
Here we systematically optimized the PM-SHIM by using a chirp analyzer to 
characterize both the spatial and temporal profiles in order to determine the optimal 
pulse compression. With the optimized PM-SHIM, we observed a significant 
improvement in SBR, as high as 3.2 times, in many biological samples. In addition, 
we were able to visualize and differentiate the collagen fibers in treated and control 
tumor samples. We have observed that collagen quantity has increased significantly in 
the treated group comparing to the control group and found a distinct difference in 
morphological features from both groups. These findings are being reported for the 
first time, to the extent of our knowledge, because of the superior excitation and 
detection sensitivity in PM-SHIM that we have developed over conventional SHIM. 
3.1 Pulse Compressor Optimization 
In figure 16, the optimization of prism positions in the pulse compressor to obtain the 
best pulse modulation is shown. The left column shows the pulse duration plots and 
the right column shows the pulse spectral width plots at various prism positions. The 
“Before AOM P1 out”, “After AOM P1 out” are the plots when prism 1 is pulled out 
of the beam path bypassing the pulse compressor. The “Before AOM P2”, “After 
AOM P2” and “At sample stage P2” are the plots at various positions of prism 2 at an 
optimized prism 1 position. The optimized prism 1 position was found to be 1100 and 
the optimized prism 2 position was 2100. The prism positions are controlled by rotary 
motors. 1100 and 2100 indicate the motor control positions. 
3.2 Group Velocity Dispersion analysis  
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The spectral and temporal profiles of the beam measured at 3 different locations are 
shown in Fig. 16, in which beam profile in the PM-SHIM and the conventional SHIM 
are shown in dotted and solid lines respectively. Amongst the three positions where 
measurements were taken, the most significant improvement is seen at location B, 
after AOM, where the pulse spectral width reduced from 14 nm to 13.18 nm in the 
PM-SHIM and the pulse duration improved from 215 fs (conventional SHIM) to 96 fs 
(PM-SHIM). From Fig 17 we can also see that dispersion introduced by the optical 
components affects mostly the pulse duration instead of the pulse spectral width. 
GVD affects the velocity of different frequencies and not the wavelength of the light.  
Also, we can see that the most dispersive component in the beam path is the AOM, 
and it has increased the pulse duration to 215 fs. By applying the pulse compression in 
the PM-SHIM system, the pulse spectral width can be reduced to 96 fs.  
The pulse duration measurement at the sample stage was taken from the reflection 
of the signal from the sample stage. The components in the microscope path could 
have introduced asymmetry to the pulse shape at the sample stage. In effect the light 
is travelling through the microscope components twice and the pulse duration 
measured at the end point was 115 fs. Thus the pulse duration of the beam reaching 
the sample is estimated to be lesser than 115 fs and more than 96 fs (pulse duration 




Figure 15: Chirp analyses of laser beam of the PM-SHIM shows a distinct temporal 
profile improvement after AOM.  
Spatial profile – pulse spectral width in nm (left column) and temporal profile – pulse duration in 
fs (right column) of the laser beam before AOM, after AOM and at the sample stage are shown. 
The dotted line represents PM-SHIM and the solid line represents conventional SHIM. The 
dispersion affects the pulse duration rather than the pulse spectral width. The pulse duration 
profile is symmetric and centered after pulse modulation. The improvement in the PM-SHIM 
can be distinctly seen in the temporal profile after AOM which introduces the maximum 




Figure 16: Chirp analyses of the laser beam of the PM-SHIM for optimization of prism positions 
in the Pulse compressor.  
Pulse duration in femtosecond (fs) and pulse spectral width in nm for different prism positions in 
the pulse compressor are obtained before AOM, after AOM and at the sample stage. The “Before 
AOM P1 out”, “After AOM P1 out” are the plots when prism 1 is pulled out of the beam path 
bypassing the pulse compressor. The “Before AOM P2”, “After AOM P2” and “At sample stage 
P2” are the plots at various positions of prism 2 at an optimized prism 1 position. The maximum 
pulse duration after dispersion is 215.48 fs and the minimum pulse duration after modulation is 
96.31 fs. The optimized prism positions are 1100 for prism 1 and 2100 for prism 2. The prism 







3.3 Signal to Noise Ratio improvement in the PM-SHIM 
SHG images from collagen gels, liver, and muscle sections in the conventional SHIM 
and PM-SHIM are shown in Fig 18.  The SHG image obtained from the collagen 
fibers in the gel construct using the conventional SHIM ( Fig 18a) are not clear while 
those obtained using PM-SHIM are brighter and sharper (Fig 18d). Fig 18b and 18e 
shows the bile canaliculi in liver, imaged with conventional SHIM and PM-SHIM. 
The SHG signal generated by collagen is shown in the green channel and the two 
photon excited fluorescence (TPEF) in the hepatocytes is shown in the red channel.  
The smaller collagen fibers surrounding the bile canaliculi are clearly visualized with 
PM-SHIM but not with SHIM. Similarly, with mouse thigh muscle, the individual 
muscle fibers and the collagen fibrils surrounding the muscle fibers cannot be 
visualized with conventional SHIM (Fig 18c) but only can be seen with PM-SHIM 
(Fig 18f).The ratio of SBR from PM-SHIM and SHIM is shown in the lower right 
corner of the images. On average, there is a 3.3±0.9 fold improvement for collagen 
gels, 2.5±0.7 fold increase for liver tissue and 2.1±0.4 fold SBR improvement in 
muscle samples. 
We have demonstrated a marked improvement for collagen visualization with 
more than two fold improvement in SBR. As SHG is a stain-free imaging system, the 
SHG signal intensity observed correlates directly to the collagen amount present in 
the sample rather than the quantity of dye present in the sample. It also helps in faster 
sample preparation making it a quick and easy technique for imaging biopsy samples, 
where the tissue can be imaged using PM-SHIM and then taken for other routine 
histology techniques.  
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Figure 17: Collagen gels, liver sample and muscle sample demonstrates improvement of SBR 
with PM-SHIM.  
Samples demonstrating the improvement of SHG and TPEF signals in collagen gels (a, d) liver 
tissue slice (b, e) and mouse thigh muscle (c, f). The improvement in Signal to Noise Ratio is 
mentioned on the improved images in the right bottom corner. The visualization of small collagen 
fibres in the liver sample (e) and the collagen fibrils in the muscle sample (f) is made possible 
with pulse modulation. Scale bar: 50μm. 
 
3.3 Collagen modulation upon drug administration visualized with PM-SHIM 
The in-vivo activity of ABT-869 on MV4-11 xenograft tumors have been published in 
Zhou et al [157]. The tumors were reduced to unpalpable size but the tumors were not 
completely eliminated by the drug treatment. In the conventional SHIM, not all 
collagen fibers can be visualized even with maximized laser power and detector 
sensitivity (Fig 19a and 19b). When looking at the same region with PM-SHIM, after 
optimizing the system (both laser power and detector sensitivity was not maximized), 
collagen fibers can be visualized clearly (Fig 19c and 19d). Only by using PM-SHIM, 
the collagen fiber content between control and the treated groups can be clearly 
differentiated.  
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Collagen fiber contents in the tumors were quantitatively analyzed.  The collagen 
fiber number and collagen area percentage of the treated and control tumors are 
shown in Fig 20. The drug-treated group is shown in white bar and the control group 
in black bar, for both PM-SHIM and conventional SHIM systems. We have found 
that, using PM-SHIM, the number of collagen fibers is much higher in the drug-
treated group (Fig 20a , 3470.8±1092 fibers /mm
2
) than the control group (Fig 20a, 
1131.7±315 fibers /mm
2
) with p< 0.0002. In the conventional SHIM, the fiber 
numbers were 1208.6±107.3 fibers/mm
2
 for the treated group and 386.9±104 
fibers/mm
2
 for the control group with p< 0.079. As shown in Fig 20b, using PM-
SHIM, the collagen area percentage of the drug-treated group was 7.9±3% while that 
of the control group was 2.0±0.2%. In the conventional SHIM, the percentages were 
2.1±0.7 % and 0.8±0.3% for the treated and control group respectively. On comparing 
the treated and control samples using a Student's t-test, the percentage calculated from 
the PM-SHIM images showed a statistical significance of p< 0.0004 and for the 
conventional SHIM it was p< 0.094.  
On quantifying the collagen fiber lengths and widths, we found that we were able 
to detect longer and wider fibers in the treated group using PM-SHIM. The longest 
fiber we detected in the treated group using PM-SHIM was 155.2 μm, while that of 
the fibers visualized using conventional SHIM was 48.8 μm. The longest fiber for the 
control group visualized using PM-SHIM was 55.7 μm and that using conventional 
SHIM was 32.9 μm. Similarly the widest fiber we detected in the treated group using 
PM-SHIM was 77 μm, while that of the fibers visualized using conventional SHIM 
was 17 μm only. The longest fiber for the control group visualized using PM-SHIM 
was 12.6 μm and that using conventional SHIM was 11.7 μm. This shows that there 
were several disconnects in the fibers visualized using conventional SHIM, hence 
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segmenting the same fiber into smaller, thinner fibers. Even though the fibers were 
segmented the overall number of fibers detected was not elevated in the conventional 
SHIM, as many of the fiber signals were too weak to be detected.  
The frequency distribution of the length and width of the fibers for the treated 
group and control group imaged with PM-SHIM (solid squares and triangles) and 
conventional SHIM (empty squares and triangles) in Fig 21 I and 21 II respectively. 
Regions of the plot are enlarged to show clearly the length and width distribution of 
the fibers as Fig 21a-21d. It can be seen from the enlarged graphs that only the length 
and width distribution of PM-SHIM is distinguishable between the treated and control 
group.  
The fibers observed in the control group include thick and long fibers, representing 
more mature fibers, and some scattered, small, and thin fibers which appeared as 
speckles, representing less mature fibers or degrading fibers. In the treated group, we 
observe branched and shorter fibers along with the long mature fibers, and the fibers 
appeared to be brighter in general. Not many speckled collagen structures were 
observed in the drug-treated group. The reduced speckle content in the drug-treated 
sample could indicate lower degradation of the collagen fiber. The brighter short 
fibers could indicate more collagen production and the long thick fibers represent 
fiber maturation in the drug-treated group. ABT-869 is a multi-targeted receptor 
tyrosine kinase inhibitor targeting mainly the Vascular Endothelial Growth Factor 
Receptors (VEGFR) and Platelet Derived Growth Factor Receptors (PDGFR). 
PDGFRs have been shown to activate collagen production in sclerosis models [158]. 
Thus ABT-869 blocking PDGFRs should theoretically down-regulate collagen 
production, which cannot explain the observed up-regulation of collagen production 
in the tumors. Thus it is more likely that the chemotherapy triggers a wound-healing 
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response resulting in the production of new collagen fibers and reduced degradation 
of the existing fibers.  
One of the hallmarks of tumor progression is reduced expression of extra cellular 
matrix especially collagen type I [159]. The collagen in the tumor interior is reduced, 
while at the tumor boundary the area of collagen (collagen cap) is increased. The 
increase in collagen in the cap has been attributed to the pushing of the pres-existing 
collagen bundles by the cancer cells onto the surrounding normal tissue [160]. The 
collagen cap is further bolstered by collagen production by activated fibroblasts. The 
collagen cap acts as a barrier to drugs [31], but when needed the barrier is broken 
down by metastasizing cancer cells [161]. In the tumor interior, the collagen fibers are 
thin and sparse as they are all newly synthesized by activated fibroblasts and cancer 
cells but not part of existing collagen bundles.  
Upon chemotherapy, when the drug diffuses beyond the collagen cap and reaches 
the tumor interior, several genes in the fibroblasts and cancer cells can be activated to 
release factors that might render the cancer cells resistant to chemotherapy. There are 
studies pointing to this effect of chemotherapy on activated stromal cells releasing 
factors, such as hyaluronic acid [162], integrins and fibronectins [163-164], that are 
often associated with local wound healing processes. A study by Farmer et al [155] 
showed that a distinct increase in the expression of stromal signature genes predicts 
resistance to chemotherapy in biopsy samples. However, none of these hypotheses 
have been directly tested by investigating the tumor responses to chemotherapy. In 
our study, we have quantified an increase in collagen fibers in the tumor interior after 
chemotherapy, which might be due to the activated stromal cells involved in local 
wound healing.  
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Furthermore, this increased collagen in the tumor interior can activate TGF- β, a 
master cytokine which in turn affects Fibroblast Growth Factor (FGF), Platelet 
Derived Growth Factor (PDGF) [165], Insulin like Growth Factor (IGF) and 
Interleukin-6 [166]. These factors exert compounding effects on the proliferation, 
activation and transformation of stromal and cancer cells. The collagen increase in the 
tumor interior can also increase the mechanical stiffness of the tissue 
microenvironment which favors cancer cell proliferation [167]. Finally, the additional 
collagen fibers can bind to pro-angiogenic factors preventing new vessel formation 
[168] thus further limiting the access of chemotherapeutic agents to the remaining 
cancer cells. Therefore, the observed increase in collagen in the tumor interior could 
impede sustained efficacy of chemotherapy through more complex mechanisms than 
previously postulated based purely on the ECM modulation observed in the tumor 
boundary [31]. PM-SHIM will provide us with a quantitative tool to further 
investigate these mechanisms. PM-SHIM can also enable us to design new regimens 
of drug treatment including collagen modulating components introduced at the 
appropriate time to reduce collagen hindrance and promote drug penetration.  
The mature fibers in the tumor interior can be visualized with the conventional 
SHIM albeit with reduced signal intensity but the small immature fibers that 
contribute to a considerable amount of collagen area are only visible in the PM-SHIM 
images. Thus using the PM-SHIM we obtained accurate quantification of collagen 
area percentage, fiber number, collagen fiber length and width, allowing us to draw 




Figure 18: Collagen fibers in chemotherapy treated samples can be clearly visualized using the 
PM-SHIM.  
Representative images of tumor samples before and after chemotherapy are shown. The top 
panels (a, b) show images taken with conventional SHIM and the bottom panels (c, d) show 
images taken with PM-SHIM. The laser power used to excite the samples with conventional 
SHIM was 10% higher than with PM-SHIM. The smaller fibers are visualized by the PM-SHIM 
which are not excited with conventional SHIM. Scale bar: 50μm 
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Figure 20: Quantification of collagen properties in chemotherapy treated samples shows 
improved fiber number and collagen area percentage with PM-SHIM.  
The collagen fiber number and area percentage are shown in (a) and (b). The two parameters are 
plotted for the drug-treated (white bars) and control (black bars) samples with PM-SHIM and 
with conventional SHIM. Statistical significance was tested with a Student’s t-test, p<0.0002** 
for collagen fiber number and p<0.0004** for collagen area percentage with PM-SHIM, and 
p<0.079* and p<0.094*, respectively, for conventional SHIM. 
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Figure 21: Quantification of collagen fiber length and width shows distinction between the 
treated and control samples with PM-SHIM.  
Graphs 1 and 2 depict the length and width frequency distribution of the treated and control 
group visualized using the PM-SHIM (solid squares and triangles) and the conventional SHIM 
(empty squares and triangles). The enlarged view of collagen fiber length distribution is shown in 
(a)and (b) and the collagen fiber width in (c) and (d). 
 
4. Conclusion 
In conclusion, we have successfully incorporated the pulse compressor in our 
SHG imaging system and validated the pulse characteristics improvement using a 
chirp analyzer as well as with biological samples like muscle, liver and collagen gel 
samples. In the drug treatment study, we were able to map out the collagen profile in 
terms of fiber length, width and numbers with and without drug administration. This 
stain free imaging method can help us quantify drug efficacy in terms of collagen 
remodeling. Due to hassle free tissue preparation technique, it can be used as a quick 
check method for faster preclinical trials and lesser drug turnaround time. Such a 
technique will be helpful in preclinical drug studies with animal models. When 
translated to clinical application, PM-SHIM can be used to study collagen modulation 
in drug treated patient samples to design better chemotherapeutic regimens that might 
include matrix modulating components. We have also validated that PM-SHIM can be 





Chapter V Characterization of the MX-1 CIC and non-CIC tumor 
models using PM-SHIM 
5.1 Introduction 
In chapter III and IV of this thesis we developed xenograft model for CIC and non-
CIC and also validated the PM-SHIM to be able to visualize and quantify small 
changes in quantity and spatial distribution of collagen. In this chapter we utilize the 
PM-SHIM to monitor the collagen changes during tumor progression and study the 
CIC-ECM interaction quantitatively. 
Our objective was to approach the CIC not just as a standalone group of cells but in 
relation to its microenvironment. At every stage of tumor progression – initiation, 
vascularization and growth the cancer cells interact with their microenvironment. The 
cancer niche is created due to the inter relationship of the extra cellular matrix (ECM) 
components, the cancer cells and the host derived cells such as the fibroblasts and 
endothelial cells. There have been several studies of cancer microenvironment either 
in vitro or in vivo with cancer cells, cell lines or bulk tumors but never with cancer 
initiating cells [169-170]. CIC have been shown to be highly tumorigenic, with higher 
expression of VEGF and more invasive than the non-CIC in various studies [15, 17, 
47]. This enhanced capacity to form and sustain tumor should be linked to how they 
interact with the matrix. The link between cancer initiating cells and the 
microenvironment in relation to metastasis was explored in a review by Sleeman and 
Cremers [171]. So far CIC properties have been studied ex-vivo where they are taken 
out of the host environment. Identifying this small group of cells in tumor tissue is not 
possible with current histology techniques. Thus instead of looking for the cells itself, 
we hope to visualize the effects of these cells on the ECM. Thus we aim to visualize 
and quantify the cell-matrix interaction of CIC in a xenograft model. 
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With the PM-SHIM system we quantify the collagen area percentage in breast cancer 
tissues isolated at 8, 12 and 16 week time points. The results provide us with an idea 
as to how collagen changes during the course of tumor development. We then image 
the relationship of cancer initiating cells with collagen in the microenvironment using 
the PM-SHIM system. We develop certain indices to compare the CIC and non-CIC 
interactions with collagen. This imaging and quantification technique can be further 
developed to define tumor boundaries in clinical settings and prospectively identify 
CIC in patient samples. 
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5.2 Materials and Methods 
5.2.1 MX-1 Breast Cancer and CIC xenograft model 
Cell Culture and CIC isolation: GFP labelled breast cancer cell line MX-1 was 
routinely cultured in T-75 culture flasks in RPMI-1640 culture medium with added 
10% Fetal Calf Serum, Sodium bicarbonate, Sodium Pyruvate and Penicillin – 
Streptomycin mixture. Cells were harvested using a Trypsin – EDTA solution, 
viability was checked with Trypan Blue and 10 million cells were prepared for 
injection.  
CIC and non-CIC were isolated using the side population method and cultured for 2 
days to allow them to recover from the stress of sorting before administration to 
animals.  
Animals: All animal work was approved by the IACUC of National University of 
Singapore and Biological Resource Centre.  3-4 weeks old Female severe combined 
immunodeficiency mice (17–20 g, 4–6 weeks old) were purchased from Animal 
Resources Centre (Canning Vale, WA, Australia) and checked for any illnesses. It 
was ensured that they were healthy before the injection of the cancer cells.  
On the day of injection, 100,000 CIC, 10 million non CIC and 10 million unsorted 
cells were trypsinized, counted, spun down and resuspended in 200 μL of chilled 1X 
PBS. The cell suspension was injected subcutaneously in the right flank of the mice. 
Sorting, cell culture and injection was done for consecutive four weeks to have four 
CIC and four non CIC SCID mouse model. 12 animals were injected for the unsorted 
group. Tumour growth and animal weight and health were monitored regularly.  
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5.2.2 Tissue isolation, sectioning and Staining 
3 animals in the unsorted group were sacrificed each at 8, 12 and 16 weeks. All the 
CIC and non-CIC animals were sacrificed at the 8 week time point. The animals were 
anesthetised using 90mg Ketamine and 9 mg Xylazine mixture. The skin flap was 
opened; chest cavity was exposed to perform a cardiac perfusion of saline to flush out 
blood and then 4% Paraformaldehyde (PFA) to fix the tissues. The fixed tumour was 
stored in 4% PFA in room temperature overnight and then transferred to 30% sucrose 
solution for 48 hours. 
The tumour was cut to manageable sizes and mounted on a cryostat chuck using 
Tissue Freezing medium. A standard cryosectioning tool is used to cut tissue slices of 
40 um, 20 um and 10 um for imaging and staining purposes. 
Statistical analysis 
We performed student t-test for two group comparisons. 
 82 
 
5.2.3 Image Acquisition, Processing and Quantification 
The 40 um tissue section was fixed in ethanol for 10 mins and washed in 1X PBS and 
de-ionized water for 10 mins each to remove the remnant OCT solution. A 0.22 mm 
coverslip is mounted on the glass slide over the tissue section and it is imaged using 
the Non linear Optics incorporated confocal microscope (Carl Zeiss LSM 510 Meta 
NLO). The excitation Ti Sapphire laser (Mai Tai, Spectra Physics, Mountain View, 
CA) wavelength is 900nm and the SHG signal from the collagen in the tissue passes 
through a 450 nm band pass filter and collected using a photomultiplier tube (PMT) 
(Hamamatsu, R6357). The two photon excited fluorescence (TPEF) from the GFP 
labelled cells and the adipose tissue are collected using another PMT after it passes a 
685 nm short pass filter in reflection mode. Images were acquired using a 0.45 NA, 10 
x Objective. 
For the unsorted group, we obtained 4 image stacks per animal, 3 animals per time 
point at 8, 12 and 16 weeks. Tile scan images were acquired of both the tumor 
boundary as well as the tumor interior. Tumor boundary was assessed based on the 
H&E staining. The collagen signals (SHG) were quantified using Matlab. The RGB 
images were separated into three channels. The collagen channel data was thresholded 
and converted to a binary file. Then it was filtered using a 3x3 median filter, eroded 
and dilated. The pixels were counted and an area percentage of collagen with respect 
to the entire image was calculated.   
Images were obtained from the four CIC tumor samples, one non CIC tumor sample 
and four non-CIC sites of injection. Individual color channels (SHG-Green, TPEF-
Red) were extracted from the images and the background was removed by 
 83 
thresholding. The SHG channel images were then converted to binary format and the 
collagen signal was counted as the number of pixels in the image. The collagen area 
percentage was calculated as the ratio of the collagen pixels to the total number of 
pixels in the image. The calculations were performed for 30 images from each tumor 
sample and the average was calculated. 
An image segmentation algorithm based on mixture Gaussian model was performed 
to remove background and noise. It is assumed that the intensity of pixels in the image 
can be modeled as the mixture of two Gaussian distributions, one representing 
collagen area with strong SHG signals and the other representing the background. 
Using the Expectation-Maximization (EM) algorithm [172] the parameters of the 
Gaussian distributions which model the intensity of pixels in the image best could be 
found. A binary image was generated by applying value 1 to all the pixels having 
intensity which belongs to the Gaussian distribution representing collagen area and 
value 0 to the rest pixels.  
The binary image was then divided into small blocks and the overall collagen fiber 
orientation in each block was calculated using the Fourier transform (converting the 
orientation of individual fibers into a frequency distribution of number of fibers at 
each orientation) as in [173]. The collagen fiber was characterized using angle index 
(AI) and neighbor index (NI) similar as in [174]. The angle index is quantified as the 
sum of the differences in the orientation of the index block and that of each of its 
neighbor blocks normalized to n, the number of neighbors used in the computation. 
The neighbor index refers to the number of nonparallel neighbor blocks, while a  
neighbor block is defined as nonparallel if the difference between its orientation angle 
and that of the index block is greater than a threshold.  The angle index and the 
neighbor index were calculated for the entire tumor as well as the regions near the 
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boundary. Different sizes of the block were evaluated, and it was found that the block 
size will not affect the quantification results of AI and NI when it is smaller than 100 
pixels by 100 pixels.  
   
 
  
Figure 22: An example to demonstrate the quantification of Angle index and neighbor index.  
a and c are the SHG images. The fiber orientation is Fourier transformed and a resultant 
orientation for every 100×100 pixel is computed as in b and d. The plots in e and f show the 
distribution of fiber angles in the 100×100 pixel area. In the top panel almost all of the fibers 
have similar orientation, while in the bottom panel the fibers are not aligned in any particular 
direction. 
 
The boundary regions of the tumor were divided into small block with 100 pixels 
deep from tumor surface and 100 pixels in width. In each block, the collagen fiber 
network was extracted using the algorithm in [175]. The angle between each collagen 
fiber and tumor surface was calculated and a histogram was generated. 






a b c 
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Figure 23: An example to demonstrate the fiber orientation quantification along the tumor 
boundary.  
a shows an image of the tumor boundary. b shows the 100 pixel long by 100 pixel wide area 
extracted from the tumor boundary. c is the quantified individual fibers in the area b.  Each fiber 
is shown in a unique color. The fiber orientation with respect to the boundary angle is calculated. 
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5. 3 Results 
5.3.1 Monitoring tumour progression using PM-SHIM 
Breast tissue samples were imaged using the conventional SHIM and the PM-SHIM. 
Both the tumor interior and the boundary were imaged. The tumor cell mass and 
collagen showed enhanced TPEF and SHG signal after with PM-SHIM. Fig 23a –c, 
23d -f shows tile scan images of the tumor at three different time points 8, 12 and 16 
weeks imaged with conventional and PM-SHIM respectively. The collagen fibre 
aggregates with tumor progression with an overall increase in collagen signal and 
reduction of small fibres in the tumor interior. The collagen area percentage was 
quantified and plotted as shown in Fig 23e. As the tumor progresses both the cell 
mass and collagen intensities increases. With PM-SHIM there is an increasing trend 
in the collagen area percentage while in the conventional SHIM the percentage seems 
to reach a plateau. There is a non-linear relationship between the amount of collagen 
and the signal generated. The laser beam in the conventional SHIM is not able to 
excite all the collagen fibres in the sample leading to a considerable reduction in the 
signal collected. The smaller collagen fibres were visualised clearly and in 3D 
imaging connected fibre network were seen which were not visualised in the 
conventional SHIM. In summary we were able to quantify the collagen and cell 
density in breast cancer tissue and capture the trend of these parameters accurately. 







Figure 24: Representative images of tumor samples at the early, mid and late time points of 8, 12 
and 16 weeks. 
 The top three panels (a-c) show images taken without pulse compression and the bottom three 
panels (d-f) show images taken with pulse compression. The collagen area percentage was 
quantified and it was plotted for the three time points. The trend in collagen area percentage 










5.3.2 CIC formed tumors remodels collagen extensively in the tumor interior 
The SHG tile scan (TS) images of non-CIC and CIC are shown in Fig 24a and 24c. 
The 10x images of non-CIC and CIC tumors are shown in Fig 24b and 24d. The 
collagen amount and distribution is distinct in case of CIC compared to non CIC. The 
collagen area percentage was found to be lower in CIC compared to non-CIC. In the 
CIC tumors collagen area percentage varied from a minimum of 1.5% in one tumor 
sample to a maximum of 14% in another tumor sample. The average collagen area 
percentage was 10.02%±0.4%, while in the case of the non-CIC tumor sample the 
collagen area percentage was 30%.   
On collagen fiber orientation analysis, as shown in Table 25a and 25b, it was found 
that the average angle index and neighbor index for CIC tumor interior was 69.55 ± 
0.55 and 3.12 ± 0.014 respectively and for non-CIC tumor the values were 62.42 ± 
0.32 and 2.88 ± 0.006 respectively. The angle index and the neighbor index of the 
stroma near the tumor boundary for CIC was found to be 60.80 ± 0.69 and 2.22 ± 0.04 
respectively and for non-CIC tumors the values were 55.30 ± 10.2 and 2.47 ± 0.58. 
The higher the angle and neighbor index the more misaligned the fibers are with 
respect to each other. Thus in the tumor interior, the fibers in CIC tumors look more 
misaligned than the non-CIC tumors. But when the region near the tumor boundary is 
quantified, the CIC collagen fibers are well aligned compared to the non-CIC tumors. 
Also the difference in alignment between CIC tumor interior and boundary is 
significantly different compared to the non-CIC tumor interior and boundary. The 
histogram in Figure 25c shows the distribution of fiber orientation in the tumor 
boundary with respect to the angle of the boundary. The number of fibers aligned 
perpendicular to the boundary was significantly higher in CIC tumors, while the 
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number of fibers aligned parallel to the boundary was significantly higher in the non-
CIC tumor.  
 
Figure 25:  CIC remodels the collagen matrix more than non-CIC 
Second Harmonic Generation (SHG) images of non-CIC cohort (a, b) and the CIC cohort (c, d) 
are representative images showing a tile scan (TS), projection of an image stack (10X). Tile scan 
images were acquired using 10X objective and stitched together as a single image. The red 
channel depicts the cells and the green channel the collagen.  Image stacks were acquired of the 
40 um thick sample and the projections of the green channel were reconstructed to show collagen 





Figure 26: Collagen fibers in CIC tumors are aligned perpendicular to the boundary 
Angle indices and Neighbor indices for CIC interior and boundary are given (panel a). the 
interior fiber orientation is significantly different from the boundary fiber orientation. In the 
non-CIC case (panel b), the AI and NI are not significantly different in the interior and boundary 
regions. The fiber orientation with respect to the boundary of the tumor is shown (c). The fibers 
in non-CIC are significantly oriented parallel to the tumor boundary while the CIC are oriented 





Second Harmonic Generation (SHG) imaging is a powerful tool for observing 
collagen in tissue samples without the need for staining, with no problems of photo 
bleaching and with increased depth of imaging of up to 250 μm. SHG imaging 
revealed that the CIC tumor interior had well remodeled collagen fibers and the fibers 
were sparse in nature. The collagen distribution in the non-CIC tumor was dense with 
matted matrix. 
In the initial phases of tumor development the matrix provides the much needed 
support and chemical cues for the cancer cells to establish a tumor but as the tumor 
development progresses the collagen molecules will be remodeled to support cell 
proliferation, expansion, angiogenesis and possibly metastasis. SHG imaging of 
collagen in cancer models have been qualitatively demonstrated in melanoma, breast 
cancer, cervical and ovarian cancer in animal and human studies [136-140]. In the 
case of melanoma [31] the skin is a relatively accessible organ with a rich supply of 
collagen and hence backward SHG of collagen fibers up to the depth of the melanoma 
capsule is possible; but within the actual tumor mass in melanoma the collagen fibers 
are reported to be sparse [176] . In case of solid tumors deep inside the host tissue, 
some studies focused on the stromal regions surrounding the tumor [177-178] , while 
the others who imaged the regions within the tumor qualitatively observed disruption 
in collagen fibers and loss of fine fibrils [139, 179-181]. Quantification of the fibers in 
the tumor interior have been reported to be difficult [32]. Using the pulse-modulated 
second harmonic imaging microscope (PM-SHIM), we were able to visualize 
collagen both within the tumor and the boundary of the tumor and quantify the 
collagen changes as the tumor grows. The collagen trend in the PM-SHIM images 
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show a linear increase in fiber content in the tumor while without pulse compression 
the fiber content seems to plateau.  
Even though there are several studies where SHG imaging of cancer has been 
demonstrated, the in-depth quantitative comparison of collagen patterns is lacking. 
Wolf et al [Wolf K, 2009] describe three dimensional movements of cancer cells 
through in vitro 3D collagen matrices. The in vitro imaging of cancer cell invasion is 
useful to understand how cancer cells change themselves as well as their surroundings 
in the process. But several other factors come into play when the cancer cells are 
growing together in a solid tumor such as vascularization and other cell types in the 
tumor. One of the landmark article that performed a quantitative comparison of 
collagen signatures in breast cancer in vivo is by Provenzano et al [140] describing 
the tumor associated collagen signatures where the collagen density above and around 
the tumor is increased and the collagen in the non-invading areas of the tumor to be 
parallel to the boundary. Keely et al. defined tumor associated collagen signatures at 
tumor host tissue interface where fibers were perpendicular to the surrounding host 
tissue at invading regions in collagen overexpressing mouse models [182]. Few other 
groups working on SHG imaging of tumors have reported that very less collagen 
fibers can only be visualized in the tumor interior in their models and they mainly 
study the boundary where the implanted tumor meets the native tissue [Hompland, 
2008][Kirkpatrick, 2007].  
We quantified the collagen fiber orientation both in the tumor interior and tumor 
boundary using two parameters –angle index and neighbor index. The entire image 
was divided into 100 µm x 100 µm blocks. The angle index indicates how well the 
fibers are aligned in a block with respect to its surrounding 8 neighboring blocks and 
the neighbor index indicates the number of misaligned neighboring blocks. The higher 
 93 
the indices the more misaligned the fibers are with their neighbors. When the AI/NI 
was compared in the tumor interior and boundary of CIC tumors, there was significant 
reduction of AI/NI from the tumor interior to the boundary, suggesting that the fibers 
are more aligned in the boundary compared to the interior. The fibers which were 
misaligned in the tumor interior assemble near the tumor boundary. In case of non-
CIC tumors the fiber alignment changes from the interior to boundary but it was not 
significant.  
We went on to quantify the alignment of all the fibers in the tumor boundary. We 
have seen that in CIC tumors, near the boundary about 40% of the collagen fibers are 
aligned perpendicular to the boundary. This could be a hallmark of an expanding 
tumor mass. The expanding phenotype of CIC might be related to their higher 
migratory and invasive potential. The possible lack of non-CIC’s ability to migrate 
and invade and to perform efficient matrix remodeling could have resulted in not 
forming tumors in most of the animals and poor structural development. These CIC 
associated collagen signatures can be identified in more animal models and patient 





In the breast cancer study, with the improved system we were able to acquire better 
quality signal with higher signal to noise ratio and also the capability to pick up 
signals from small collagen fibres. We were able to map out the collagen profile as 
the tumor progresses. Areas where the cancer cells have broken the collagen fibres 
where the boundary is considerably thin can be seen. These collagen reduced areas 
maybe the regions where the tumor expands and invades the surrounding tissue. With 
such improved system a grading system can be established from the various stages of 
cancer progression based on collagen status. The metastatic status can be assessed 
based on the collagen density in the tumor boundary. Such a technique will be helpful 
in preclinical drug studies with animal models. This stain free imaging method can 
help us quantify drug efficacy in terms of collagen remodelling and tumor staging. It 
can be used as a quick check method for faster preclinical trials and lesser drug 
turnaround time. With improved accuracy and repeatability we can extend the staging 
system for human samples. Biopsy samples can be imaged easily using the 
SHG/TPEF system and tumor stages can be determined reducing the need for tedious 
histopathological technique.  
The SHG imaging technique is a quantitative imaging method with great potential for 
clinical applications. As Keely and her colleagues have shown that there could be 
tumor associated collagen signatures, there might be CIC associated collagen 
signatures that can be identified in animal models and patient samples. With such 
collagen signatures, clinicians might be able to assess the presence of CIC in patient 
samples and design treatment regimens to improve patient prognosis.  
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VI Conclusions 
This thesis has documented the establishment of a cancer initiating cell isolation 
model, improvement of a conventional Second Harmonic Imaging Microscope 
(SHIM) with a pulse modulation system to develop the PM-SHIM and studying the 
CIC ECM relationship in a xenograft model. We used the side population technique to 
isolate CIC from a breast cancer cell line MX-1 and shown that the CIC had better 
survival, proliferation, drug resistance, migration and invasion. The CIC isolated 
through side population method has higher expression of CD44 and lower expression 





 profile. Our result indicates that the population we isolate using side 
population method is the same as the one isolated using the marker profile. CIC when 
injected in animals formed better tumors than non-CIC even when tenfold fewer cells 
were injected. Thus with a comprehensive in-vitro and in-vivo study we established a 
method to isolate CIC and develop xenograft models from the breast cancer cell line 
MX-1. 
We intended to approach the problem of CIC in relation to its extra cellular matrix 
and decided SHIM as the most suitable tool to study the CIC-ECM relationship. We 
introduced pulse modulation to the conventional SHIM and optimized the pulse 
modulation using Chirp analysis. The improved system was called pulse modulated 
SHIM (PM-SHIM). We reduced the group velocity dispersion and delivered the 
maximum excitation to the sample thus obtaining a twofold improvement in the SBR 
in the PM-SHIM compared to the conventional SHIM. To demonstrate this 
improvement we used the collagen gels, liver tissue slice and muscle sample and in all 
the biological sample we demonstrated that finer details could be obtained using the 
PM-SHIM which were missed by the conventional SHIM.  
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We used a chemotherapy model to assess the effects of drug administration to 
collagen content in the tumor as well as compare the performance of PM-SHIM to the 
conventional SHIM. We identified clear quantitative differences between the treated 
and control tumor samples. The collagen content increased after treatment which 
might offer the tumor a protective barrier against further drug diffusion into the 
tumor. This collagen content increase was only visualised using the PM-SHIM. We 
can use this study to assess patient biopsy samples before and after treatment. We can 
develop new treatment regimens to administer matrix remodelling drugs to intervene 
collagen production at appropriate times to enable the effect of chemotherapy. 
With the PM-SHIM, we studied the CIC-ECM relationship with collagen as our 
molecule of interest. We quantitatively determined that CIC tumors had much lesser 
collagen content compared to non-CIC tumor. We analyzed the images to identify the 
orientation of the collagen fibers in the tumor interior and tumor boundary. The 
collagen orientation information indicates that in CIC tumors the collagen fibers are 
aligned significantly perpendicular to the boundary, while in non-CIC tumor the fibers 
are aligned parallel to the tumor boundary. The fibers aligning perpendicular to the 
tumor boundary might indicate an expanding tumor boundary. This fiber orientation 
phenotype might indicate presence of CIC in tumor samples. In future studies the 
collagen fiber orientation in patient samples can be quantified to assess presence of 
CIC and help tailor therapies. In conclusion, we have established a tool to 
systematically study the cancer initiating cells and ECM relationship and identified 
unique collagen pattern and signatures specific to CIC in xenograft models. This 
imaging and image quantification tools can be used for pre-clinical and clinical 
studies to identify CIC and may be used to develop therapies targeting CIC. 
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VII Recommendations for future research 
7.1 SHG imaging of pre-clinical trial samples and drug administered 
patient samples to evaluate collagen dynamics after drug treatment and 
derive meaningful relationships 
The extracellular matrix has been shown to be a diffusive barrier to chemotherapy 
{Horning, 2008 #117}. The alteration of this barrier has resulted in improved drug 
penetration into the tumor {Brown, 2003 #103}. This in turn would result in better 
killing of cancer cells. We have demonstrated that upon drug administration, this 
ECM barrier to therapy increases. We have quantified this ECM change in terms of 
collagen fibers and have ascertained that the collagen area percentage increases four 
folds and there are significant increase in fiber number, fiber length and width.  
We can use this imaging and image processing tool developed for animal models in 
pre clinical trials to ascertain the time frame in which the increase in collagen takes 
place by sampling at different time points of the treatment. Collagen dynamics with 
drug administration can give us insight into the chemo-protective response by the 
cancer cells. We will be able to identify drugs that elicit such a response and these 
drugs might work better in combination with matrix modifying components. The 
collagen dynamics will reveal the time point at which the cancer cells increase 
collagen content. The combination chemotherapy and matrix modifying components 
such as relaxin can be administered during the correct treatment window revealed by 
the collagen dynamics information. When administering the combination of 
chemotherapy and matrix modifying components, we can assess the collagen changes 
again and enquire if the treatment is more effective than the chemotherapy alone. We 
can build a database of the collagen dynamics of various chemotherapy molecule and 
identify the best combinations to deliver maximum drugs to the cancer cells and 
ensure eradication of the tumor mass.  
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We can translate the study to patient biopsy samples. The biopsy samples from the 
treated and control group can be obtained from the tissue repository. The collagen 
content change of these biopsy specimens under various drugs regimens can be 
identified. Also fresh biopsy samples from patients undergoing therapy can be 
imaged. As PM-SHIM technique is a non-invasive, stain-free imaging technique, the 
biopsy sample can be used for other histology techniques after PM-SHIM imaging. 
This way the collagen dynamics of individual patients can be tracked through the 
treatment as and when biopsies are taken. The increase in collagen content can 
indicate to the clinician that the cancer cells are eliciting a chemo-protective response 
and hence they need to change the treatment regimen.  
We have developed specific image processing algorithms to quantify collagen fiber 
properties in animal models. These algorithms can be adapted and developed to suit 
patient samples and give accurate quantitative information for pre-clinical studies and 






7.2 SHG imaging of patient samples to identify cancer initiating cell niches 
in tumors to help design appropriate therapies 
The ubiquitous presence of extra-cellular matrix and its chemical and mechanical role 
in tumors have been well documented {Ghajar, 2008 #336;Ingber, 2008 #337}. 
Several different ECM molecules roles have been studied in various tumor types. 
Collagen is one such ECM molecule which is found abundant in the 
microenvironment. The concept of CIC in patient samples and their implication in 
treatment failure is steadily gaining ground. We have identified that collagen is 
remodelled extensively in tumors initiated by CIC compared to tumor formed by non-
CIC. The collagen percentage is significantly lower in CIC tumors and also the fiber 
orientation is distinctly different compared to that of non-CIC tumors. We have 
identified an unique collagen signature along the tumor boundary where the fibers are 
distinctly aligned perpendicular to the boundary. The fiber alignment might indicate 
an expanding or invading tumor mass compared to that of the non-CIC where the 
fibers are aligned more parallel to the tumor boundary. 
We propose that such collagen signatures can be identified in patient samples. We can 
conduct preliminary studies from tumor explants. Some tissue sections can be used to 
do SHG imaging and we can obtain sufficient cell numbers from the tumor explants to 
ascertain the presence of CIC using techniques such as side population method or 
markers such as CD44/CD24. Thus the collagen patterns from tumor samples can be 
correlated with presence or absence of CIC. Based on the pilot studies we can develop 
CIC associated collagen signatures. Appropriate image processing algorithms can be 
developed to identify these signatures accurately and rapidly from SHG images of the 
tumor samples. The collagen pattern can also be correlated to the prognosis factors 
such as tumor size, lymph node involvement, estrogen receptor/ progesterone receptor 
status, Her2/ neu status. All these prognostic factors help clinicians to decide if the 
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disease would recur or not. Thus through the collagen signatures, CIC presence can be 
linked to the risk of recurrence of tumors. 
Once the SHG imaging system and image processing techniques are set up, we can 
image biopsy samples obtained for histo-pathology. The tissue slices can be imaged 
and it later can be used for other staining purposes. The collagen signatures will be 
identified during image analysis. Based on the collagen signatures presence or 
absence of CIC can be determined. There are several new strategies being developed 
to stifle the CIC and prevent chemoresistance and tumor recurrence. The clinician can 
make an informed decision about the treatment strategy that will be adopted to target 
and eradicate the CIC.  
With SHG imaging of tumor tissue obtained post operation, we can determine 
collagen signatures indicating presence of CIC and predicting the risk of recurrence of 
the disease. Based on the assessment, patients can be advised suitable follow-up 
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